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 Traditional methods of drug delivery to the eye include topical application, 
intraocular injection and systemic administration; however, each method has its 
limitation to efficiently deliver drugs to the back of the eye.   Therefore, developing more 
effective ocular drug delivery methods with fewer vision threatening complications is 
essential to improve the treatments of posterior segment ocular diseases.  Microneedles, 
which were developed for transdermal delivery, have the potential to deliver drug across 
the ocular tissues in a minimally invasive way because of their small size.  To test this 
hypothesis, the goals of this study were (1) to provide experimental measurements 
coupled with a theoretical modeling to quantify the distribution of a model compound 
during lateral diffusion within the sclera in vitro, (2) to assess the capability of using 
coated solid metal microneedles to deliver drugs into the ocular tissue in both in vitro and 
in vivo scenarios and (3) to infuse solutions into the sclera tissue in vitro using hollow 
glass microneedles and examine the physiological barriers for flow. 
 To familiarize with the drug diffusion properties within the sclera, we first 
measured the lateral diffusion of a model compound, sulforhodamine, through human 
cadaver sclera.  Experimentally, we determined that lateral diffusion of sulforhodamine 
depended strongly on both time and position along the tissue.  The measured sclera-to-
saline distribution coefficient of 13.6 indicated significant binding between molecules 
and tissue.  These data were fitted to a theoretical model, which yielded an effective 
lateral diffusion coefficient for sulforhodamine of 3.82e-6 cm2/s.  This finding suggested 
that a point source of sulforhodamine would take up to 6 weeks to diffuse throughout the 
sclera in a human eye.  Comparison with transscleral diffusion indicated similar diffusion 
 xx
coefficients, although lateral diffusion was approximately three times faster.  This study 
presented the first experimental data on lateral diffusion within the sclera.  Using the 
developed theoretical model, drug distribution in the sclera can be estimated for various 
drug delivery scenarios, for example, from an implant. 
 This work also studied the use of solid metal microneedles, having lengths of 500-
750 µm, to deliver drugs into the eye.  Using a specially formulated coating solution, 
these needles were coated with compounds of various sizes (fluorescein, DNA and 
proteins).  In vitro insertion tests showed that the microneedles were mechanically strong 
enough to penetrate into human cadaver sclera, and the coating solution rapidly dissolved 
off the needles after insertion and had been deposited within the tissue.  We then assessed 
this system in an in vivo animal model, in which single, fluorescein-coated microneedles 
were inserted into the rabbit cornea for delivery.  Fluorescein concentration in the 
anterior segment of the eye was immediately increased after needle insertion, reached to a 
peak value after 3 h, and decreased to background level with 24 h.  Compared to topical 
administration of equivalent fluorescein dose as the needle coating, microneedles showed 
a bioavailability of 60 times greater.  The administration of pilocarpine using coated 
microneedles yielded similar results, which caused rapid and extended pupil contraction.  
Safety studies reported no inflammation responses caused by the microneedle insertion.  
This the first study demonstrating the capability of using microneedles for ocular drug 
delivery to treat diseases in both anterior and posterior regions of the eye. 
 Hollow glass microneedles, fabricated using a micropipette puller, were also 
studied for delivery within human cadaver sclera.  Microneedles were inserted 720-1080 
µm into different regions of the sclera, and delivered up to 18 µl fluid on average into the 
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tissue after needle retractions of 200-300 µm.  Infusion pressure showed an insignificant 
impact on the delivery.  The main barrier in scleral delivery appeared to be the complex 
alignment of tightly packed GAG and collagen fibers, which micron-sized particles were 
unable to flow through.  The presence of either hyaluronidase or collagenase enhanced 
microsphere delivery by breaking down the fibers.  
 Altogether, this work provides the first studies of using microneedles as a novel 
tool to deliver drugs either within or across the ocular tissue for disease treatments in a 
minimally invasive way.  With further optimization, the ultimate aim of the study is to 
provide a targeted, controlled drug delivery to treat diseases, such as diabetic retinopathy 




Drug delivery to the eye using current methods is an extremely inefficient process 
by topical or systemic administration.  Intraocular injection is more efficient, but 
introduces safety concerns.  There is a demand for improved methods of drug delivery to 
the eye that increase efficiency and safety.  The principal route for local ophthalmic drug 
delivery system remains the topical application of solutions to the surface of the eye as 
eye drops.  Conventional eye drops typically act transiently, which enter the eye by either 
diffusion across the cornea or across the sclera (Robinson and Lee 1988; Lang 1995; 
Tasman 1995).  Drug delivery to intraocular tissues toward the back of the eye, such as 
retina and choroid, by this approach, however, is limited by:  (i) the significant barrier to 
solute flux provided by the corneal epithelium and conjunctiva; and (ii) precorneal drug 
losses that are due to tear drainage and tear fluid turnover (Geroski and Edelhauser 2000).  
Other drug delivery methods, such as intraocular injections or ocular implants 
demonstrated improved delivery efficiencies; however, we need to consider additional 
factors including safety issues and patient compliance.  The ideal route for drug delivery 
to the back tissues of the eye will be transscleral, due to large surface area of the sclera.  
The average 16.3-cm2 surface area of the human sclera (Olsen, Aaberg et al. 1998)  
accounts for 95% of the total surface area of the globe and provides a significantly larger 
avenue for drug diffusion to the inside of the eye than the 1-cm2 surface area of the 
cornea. 
 Over the past decade, the concept of microneedles for transdermal drug delivery 
has found acceptance, and studies have shown the potential of using microneedles to 
enhance drug delivery across the skin (McAllister, Allen et al. 2000; Davis 2003; 
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Martanto 2005).  This thesis addresses, for the first time, the possibility that microneedles 
could be used for drug delivery to the eye. While guided by the advantages of 
microneedles and their successes in transdermal studies, we are hoping to apply the same 
technique in drug delivery to the posterior segments of the eye.  Using microneedles as 
the new tool in ocular drug delivery can offer the following advantages:  (1) they may 
minimize pain and tissue damage relative to hypodermic injections because they are 
small enough to avoid simulating nerves or significant tissue trauma; (2) they should be 
well tolerated and thereby increase patient compliance since a single application might be 
suitable for long-term use; and (3) they will provide a localized and target drug delivery 
to the back of the eye. 
 Depending on the type of microneedles we use, we can improve the drug delivery 
efficiency in various fashions.  This study is mainly focused on using two different types 
of microneedles:  solid metal and hollow glass microneedles.  For solid microneedles, 
drug formulations are coated onto the shafts of the needles.  The insertion of coated 
microneedles into the sclera or cornea should deposit drug directly into the ocular tissue 
area bypassing the epithelial barriers of corneal epithelium and conjunctiva.  The coated 
drug that dissolves off the needle shaft is stored in the sclera or corneal tissue, and is 
delivered into the eye by diffusion.   Using hollow glass microneedles, we can pre-load 
drug solutions into the hollow lumen region of the needle.  After insertion into the sclera, 
the drug is injected into the ocular tissue using pressure-driven flow.  Coupling with an 
insertion device, we can precisely control the insertion depth of the needle into the tissue.  
Both methods should achieve the following goals in drug delivery to the back of the eye:  
(1) increasing the amount of drug delivered relative to topical administration; (2) more 
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localized drug delivery relative to systemic administration; (3) safer delivery approach 




2.1 Ocular drug delivery 
 A big challenge that ophthalmologists face today is effectively delivering drugs to 
the back (retinal, choroid and vitreous body) of the eye.  The most conventional way of 
ocular delivery is using eye drops, but only a small amount of the drug can actually reach 
the targeted area.  Most of them are washed away by the tear fluid on the surface of the 
eye. Alternative methods, such as intraocular injections and implantation, offer better 
delivery efficiency; however, complications associated with safety and patient 
compliance must be considered.  The development of microneedles showed excellent 
potential as a novel drug delivery tool for transdermal drug delivery (Trimmer, Ling et al. 
1995; McAllister, Wang et al. 2003; Martanto, Davis et al. 2004).  They could minimize 
tissue damage with their small size and provide targeted delivery.  Using the same 
concept, microneedles might be used in ocular drug delivery to treat diseases such as 
macular degeneration and diabetic retinopathy.  The thesis addresses this concept for the 
first time. 
   
2.1.1 Anatomy of the eye 
 The human eye can be viewed as a deformed spherical shell of tissues with a 
diameter of 23-24 mm (Fatt and Wissman 1992).  Its interior is filled largely with water 
in the form of aqueous humor and the vitreous body, as well as additional structures such 
as the lens and iris.  The exterior shell of the eye consists of three layers:  the outer sclera, 




Figure 2.1.1.  Anatomy of the human eye (copied from www.mvrf.org).  
 The transparent portion of the eye is the cornea, which represents 7% of the total 
surface area on human eye.  The thickness of the human cornea in the central region is 
about 0.52 mm, thickening to about 0.67 mm at the limbus (Hogan, Alvarado et al. 1971).  
It is a multilayered tissue containing a superficial layer of epithelial cells, followed 
deeper by Bowman’s layer, stroma, Descemet’s membrane and finally a monolayer of 
endothelial cell at the base.  The cornea is considered to be the main pathway for the 
permeation of drugs into the eye (Robinson 1993), and it provides 2/3 of the optical 
focusing power for the eye. 
 The sclera is a thin spherically shaped connective tissue that gives the eye its 
shape. It is attached to the ocular muscles, which control the movement of the eye.  The 
front portion of the sclera can be seen externally as the “white of the eye”.  On its anterior 
surface adjacent to the cornea, the sclera is covered by conjunctiva, a transparent layer of 
cells.  The remainder of the sclera consists of a layer called Tenon’s capsule, a thin 
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connective tissue layer overlying the episclera.  The episclera can be distinguished from 
the sclera itself by being more loosely woven and rich in blood vessels.  The sclera is 
lined internally by the choroid, which contains blood vessels, and the retina, which 
contains the nerves involved in sight.  In the human eye, the sclera is about 0.6 to 0.89 
mm at the limbus, thinning to 0.4 to 0.5 mm at the equator and thickening again to 1.0 
mm at the posterior pole (Hogan, Alvarado et al. 1971). 
 Transport properties of the sclera are of interest relative to the transport of drugs 
applied topically to the eye, due to its large surface area.  This includes diffusion of drugs 
across the conjunctiva and sclera to the anterior segment structures (Ahmed and Patton 
1985; Edelhauser and Maren 1988) and of drugs applied directly to the scleral surface 
(Mietz, Addicks et al. 1994) to deliver drugs to the posterior pole in treatment of 
posterior segment diseases.  In addition, regional differences in scleral thickness could be 
used to further optimize drug diffusion if sustained-release delivery devices or systems 
could be placed in regions where sclera permeability was the greatest (Geroski and 
Edelhauser 2000).   
 
2.1.2 Common vision problems  
 Blindness and visual impairment extract a great price from individuals and society, 
and they are also an enormous cost to the federal government, estimated conservatively at 
$4 billion annually (Tielsch 2000).  Among people 40 years and older (approximately 
95.2 million people) in the U.S., more than 1 million are legally blind and more than 3.4 
million people are considered visually impaired.  The most common causes of vision loss 
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are age-related macular degeneration, glaucoma and diabetic retinopathy, and patients’ 
lives are greatly affected by these diseases. 
 Age-related macular degeneration (ARMD) is the most common cause of severe 
loss of central vision in people aged over 50 in the Western world (Vingerling, Klaver et 
al. 1995).  It is a disease caused by damage to tissues that provide physiological support 
to the light-sensitive cells in the retina (Figure 2.1.2).  The disease is categorized into two 
stages:  dry disease, which is the background disease, and wet disease, which occurs 
when abnormal blood vessels form as a complication of the dry disease and cause vision 
loss.  The vision loss results from loss of function of the macula, the center of the retina, 
which is responsible for central visual tasks such as reading, driving and recognizing 
faces.  Recently, therapeutic drugs, such as Macugen (Pegaptanib sodium injection) and 
Lucentis (Ranibizumab injection) have been shown to help preserving vision in patience 
with ARMD by slowing vision loss.  The recommended dose of Macugen is 0.3 mg of 
intravitreal injection administered once every 6 weeks.   Lucenis is injected intravitreally 
into the eye at a dose of 0.5 mg on a monthly basis; however, each dose costs close to 
$2000 (Jimenez 2006), which most ARMD patients could not afford if they had to take a 





Figure 2.1.2.  Age-related macular degeneration is a disease caused by formation of 
abnormal blood vessels leading to rapid vision loss (copied from www.mayoclinic.org). 
 
  
Glaucoma, the second leading cause of adult blindness in the U.S., is a group of 
diseases usually associated with an increased pressure within the eye (Figure 2.1.3).  This 
elevated pressure can cause damage to the cells that form the optic nerve, the structure 
responsible for transmitting visual information from the eye to the brain.  The damage is 
progressive with loss of peripheral vision first, followed by loss in central vision and 
potentially blindness.  About 2.2 million Americans age 40 and over have this disease.  
Because the condition does not cause symptoms in its early stages, half of patients do not 
know until it reaches the later phase (U.S.News 2006). 
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Figure 2.1.3.  Glaucoma is a disease that caused by elevation of intraocular pressure 
within the eye (copied from www.uic.edu) 
 
The treatment of glaucoma primarily entails the use of eye drop solutions containing 
drugs such as prostaglandin analogues (improving fluid drainage), beta-blockers 
(reducing the amount of aqueous humor that the eye makes), alpha-adrenergic agonists 
(lessen the amount of aqueous humor as well as increasing fluid drainage) and carbonic 
anhydrase inhibitors (reducing the amount of aqueous humor).  Normally these drops 
need to be applied to the eye 3-5 times per day, which often leads to poor patient 
compliance, especially among elders.
 Approximately 16 million people in the U.S. have diabetes, and nearly 49% of 
them are affected by diabetic retinopathy, which is an eye disease affecting the blood 
vessels in the retina.  When blood vessels in the retina are damaged, they may leak fluid 
or blood and grow fragile, brush-like branches and scar tissue (Figure 2.1.4).  This 
symptom of diabetic retinopathy can blur or distort the images that the retina sends to the 
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brain.  Recent studies show that injection of steroids can reduce the progression of the 
disease (Jonas, Kreissig et al. 2003). 
 
Figure 2.1.4.  Diabetic retinopathy is a retinal disease caused by changes in the blood 




2.1.3 Conventional ocular drug delivery methods 
The eye, like every nervous organ of the body, is naturally well protected from the 
systemic circulation.  The local delivery of drugs into the posterior segment of the eye, 
particularly into the retina, at efficient concentration with reduced local or general side 
effects, is one of the main issues ophthalmologists face today.  Currently the posterior 
segment disease treatments focus on four approaches to delivery drugs – topical, systemic, 
intraocular injection and periocular injection (Geroski and Edelhauser 2000).  A 
comparison of using each delivery method is shown in Table 2.1: 
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  Mode of delivery Advantage Disadvantages
Topical Ease of access Frequent applications 
Negligible levels in posterior 
segment
Systemic Frequent applications Ease of access
Systemic adverse reactions
Intraocular Targeted delivery Frequent applications 
Higher efficiency Complications of intraocular 
injections
Periocular Targeted delivery Low delivery efficiency
Safer
 
Table 2.1.  The advantages and disadvantages of common approaches to deliver drugs to 
the posterior segment of the eye. 
 
  
Traditional therapies include topical applications of drugs with eye drops.  This 
mode of delivery can be easily accessed; however, it requires often-repeated applications 
(up to 5 times per day).  In general, the treatment by drops is ineffective to treat the 
diseases in the back of the eye due to various barriers.  The drug is rapidly washed away 
by tears and cannot reach the vitreous body, the retina and the choroid at sufficient levels.  
Additionally, the ineffectiveness is due to the long diffusion path length, counter-
directional intraocular convection, and corneal impermeability to large molecules 
(Stjernschantz and Astin 1993; Maurice 2001). 
 Although a systemic delivery approach can deliver drugs to the eye, the 
administrated drugs have poor access to the tissues in the back of the eye due to two 
barriers:  blood aqueous and blood-retinal barriers (Stjernschantz and Astin 1993).  The 
blood-aqueous barrier, which is the anatomical mechanism that prevents exchange of 
materials between the chambers of the eye and the blood, prevents the substances from 
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entering the aqueous humor of the eye.  The blood-retinal barrier, which is a transport 
barrier formed by tightly-joined endothelial cells, severely limits drug entry into the 
extravascular space of the retina and into the vitreous.  The retinal pigmented epithelium 
also has tight junctions that form an effective barrier. Consequently, large systemic doses 
are required, and this can induce toxicity and unwanted side effects.  
 The traditional therapies of delivering drugs to the back of the eye that are more 
effective are intravitreal (into the eye) injections.  The main problem with both methods 
is that after a drug is injected, its concentration in the system decreases exponentially 
with time as the body consumes it.  This means that in order to maintain clinically helpful 
concentration of the drug in the eye, frequent injections of the drug are required.  In 
addition, the injections can potentially induce complications, such as retinal detachments, 
cataracts, infections and pain (Herrero-Vanrell and Refojo 2001; Maurice 2001). 
 In recent years, there is a regenerated interest in the periocular (around the eye) 
delivery of drugs, which the drug is interfaced with the sclera.  Drug delivered by 
periocular injection can reach the posterior segment by three main routes:  transscleral, 
systemic circulation (through the choroid) and the anterior route through the tear film, 
cornea, aqueous humor and the vitreous body (Ghate and Edelhauser 2006).  Systemic 
absorption is low via the subconjunctival route, which can lower systemic side effects 
while providing a localized drug effect (Gudauskas, Kumi et al. 1985).  
 
2.1.4 Sclera permeability 
 The sclera is an elastic and microporous tissue composed of proteoglycans and 
closely packed collage fibrils (Foster and Sainz de la Maza 1994; Newell 1996) 
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containing 70% water.  Its large surface area (16.3 cm2) (Olsen, Aaberg et al. 1998) 
provides a significantly larger avenue for drugs to diffuse into the eye than the 1-cm2 
surface area of the cornea.  Over the years, a series of studies have shown the sclera to be 
permeable to a range of drugs and solutes. Maurice and Polar (1977) have reported that 
the sclera generally offers less resistance to solute diffusion than does the cornea.  While 
the cornea is relatively impermeable to solutes having a molecular size over 1 kDa, 
dextran (40 kDa) and serum albumin (69 kDa) can readily penetrate across the scleral 
tissue (Olsen, Edelhauser et al. 1995).  More recently, Ambati et al. (2000) have shown 
the sclera to be permeable to higher molecular weight dextrans, as well as to the proteins 
IgG and bovine serum albumin, BSA).  An inverse relationship was found between 
scleral permeability and solute molecule weight.  The permeability of the sclera to 
carbonic anhydrase inhibitors is similar to the permeability of the corneal stroma 
(Edelhauser and Maren 1988).  Hydrocortisone permeability is five times greater in sclera 
than in corneas with intact epithelia (Unlu and Robinson 1998).  The scleral 
permeabilities of adrenergic blocking agents are also found to be significantly higher than 
their corneal permeability (Ahmed and Patton 1987).  In addition, a theoretical model 
(Edwards and Prausnitz 1998) was developed to predict sclera permeability for a broad 
range of molecules.  This model did not require any fitted parameters and was validated 
with steady-state transport data from 20 compounds including small drugs and 
macromolecules.  Later on, a complementary model which predicts molecule transient 
transport behavior was developed (Prausnitz, Edwards et al. 1998) and was validated with 
experimental data on carboxyfluorescein flux. 
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 Scleral permeability can be increased by scleral thinning, increasing tissue 
hydration and increasing temperature (Ghate and Edelhauser 2006).  Age, cryotherapy 
and diode laser photocoagulation do not seem to have a significant impact on scleral 
permeability (Olsen, Edelhauser et al. 1995).  Studies have shown that prostaglandins can 
improve scleral permeability by increasing expression of matrix metalloproteases and 
they can be used to enhance transscleral delivery of peptides into the back of the eye 
(Kim, Lindsey et al. 2001; Weinreb 2001; Weinreb, Lindsey et al. 2004).  A recent study 
showed that 0.01 and 0.05% benzalkonium chloride, could be used to increase 
transscleral penetration of drugs with minimal toxicity (Okabe, Kimura et al. 2005) 
 
2.1.5 Transscleral delivery 
 An ideal route to deliver drugs to the posterior segment of the eye would be 
transscleral, which takes advantages of the large surface area of the sclera.  In addition, 
regional differences in scleral thickness could be used to further optimize transscleral 
drug delivery if sustain-release delivery devices or systems could be placed in regions 
where scleral permeability was the greatest (Geroski and Edelhauser 2000).  A wide 
variety of drug delivery systems, including periocular injection, ocular implants of gel 
formulations or biodegradable polymers, and iontophoresis have shown potential for 
transscleral application. 
 A major method of drug delivery to the posterior segments is periocular injection, 
which includes subconjunctival, retrobulbar, peribulbar and posterior subtenon injections.  
This approach is safer and less invasive than intravitreal injection and also offers the 
potential for localized, sustained-release drug delivery.  Weijtens et al. (1999) found that 
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periocular injection is more effective compared with oral administration for delivering 
dexamethasome into the back of the human eye.  Lee et al. (2001) injected radiolabelled 
mannitol subconjunctivally in rabbits and concluded that, after subconjunctival injection, 
direct penetration through the sclera is the predominant pathway for drug delivery to the 
posterior segment with minimal contribution from the recirculation pathway and the 
transcorneal pathway.  
 A transscleral implant made out of either a gel formulation or biodegradable 
polymers can also be used as a minimally invasive method for drug delivery, since the 
human eye has a high tolerance of foreign bodies on the sclera (for example, the scleral 
buckle used in retinal-detachment surgery).  In situ polymeric gels, such as pluronic F-
127 and fibrin glue, are viscous liquids that on exposure to physiological conditions will 
shift to a gel phase.  Preliminary studies showed that these gels can provide slow, 
uniform sustained release of dexamethasone across human sclera (Lee, Geroski et al. 
2004) .  Yasukawa et al. (2006) investigated using biodegradable implants, composed of 
hydrophilic or hydrophobic polymers, in the shape of rods, plugs, discs or sheets, and an 
implantable rod is presently being assessed in a Phase II trial to treat macular edema 
secondary to diabetic retinopathy or branch-retinal vein occlusion. 
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Figure 2.1.5. A scleral implant of biodegradable polymer, PLA.  The device weights 8.5 
mg and is 5.0 mm long (Yasukawa, Ogura et al. 2006). 
 
Iontophoresis has been proven to increase transscleral delivery of various drug 
classes, including fluorescein, antibiotics and steroids (Sarraf and Lee 1994).  However, 
this method may cause further complications in the eye, such as retinal edema, disruption 
of the normal retinal architecture and retinal pigment epithelial hyperplasia (Lam, Fu et al. 
1991).  Further improvements may be needed with this approach.   
 
2.2 History of microneedles 
 The creation of microneedles for transdermal drug delivery seeks to combine the 
benefits of both conventional hypodermic needle injection and transdermal patches, while 
reducing the limitations associated with each technique.  The overarching motivation for 
microneedles is that they can provide a minimally invasive means to transport drug 
molecules into the tissue.  Over the past decade, numerous designs of microneedles have 
 16
been developed using tools from the microelectronic industry. Microneedles have been 
fabricated with a range of sizes, shapes and materials, from solid spike microneedles to 
biodegradable polymer microneedles to hollow microneedles.  Depending on the 
microneedle type, it can have its unique functionality.  Typically, these microneedles are 
hundreds of microns in length, on the order of one hundred microns at the base and 
having a sharp tip that is ones to tens of microns in diameter.  When scaled up to mass 
production, microneedles are likely to be inexpensive enough to be used as disposable 
devices.   
 
 
Figure 2.2.1.  Microscopic image shows a hollow metallic microneedle array (500 µm tall) 






2.2.1 Solid microneedles 
 Solid microneedles were designed to create micron-size pores in the tissue, which 
act as direct pathways allowing drug molecules or particles to transport into the tissue.  
These microneedles tend to have sharp tips and have good mechanical strength.   They 
could be mass-produced at low cost.  
 
2.2.1.1 Silicon microprobes 
 In the early phase of microneedle development, pyramidal silicon microprobes 
were found (Hashmi, Ling et al. 1995).  Using a spin casting method, a photoresist is 
placed onto a silicon-dioxide coated wafer; the wafer is then brought in contact with a 
photomask and is exposed to UV light.  The transferred pattern (from photomask to 
photoresist) is then etched into the silicon dioxide masking layer.  The photoresist is then 
removed and the wafer is anisotropically wet-etched in potassium hydroxide solution to 
create arrays of pyramidal probes.  With the goals of delivering genetic materials to cells, 
these microprobles are ten to hundreds of microns in height and have very sharp tips.  
These structures were used to transfect DNA into cells of plants (Trimmer, Ling et al. 
1995) and mammals (Reed, Clarence et al. 1998). 
 18
 
Figure 2.2.2.  A single silicon microprobe fabricated by anisotropic silicon etching and 
used to deliver genes to plant and mammalian cells (Trimmer, Ling et al. 1995).   
 
2.2.1.2 Silicon microneedles 
 The simplest forms of the microneedles are solid spikes.  Besides being solid, 
their unifying characteristics include being very sharp and usually have fairly simple 
fabrication schemes.  Using a deep-reactive ion etching method, silicon microneedles 
were fabricated.  The fabrication steps include depositing a chromium masking layer onto 
a silicon wafer, patterning it using photolithography into dots with the size of the desired 
needle base.  The wafer is etched with an oxygen/fluorine plasma mixture to create the 
high aspect ratio silicon microneedles.  These needles were used to create micron-scale 
holes in the skin through which molecules can be more easily transported. 
 Henry et al. (1998) conducted the first study to determine if silicon microneedles 
could be used to increase transdermal drug delivery.  The penetration of microneedles 
through the upper layer of skin (stratum corneum) created direct pathways for molecules 
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that would not normally be able to diffuse through skin barrier due to size or water 
solubility.  These microneedles as shown in Figure 2.2.3 were demonstrated to increase 
the permeability of in vitro human epidermis by 3-4 orders of magnitude. 
 
 
Figure 2.2.3.  Arrays of solid silicon microneedles used in transdermal drug delivery 
study and demonstrated enhancement of dermal permeability (Henry, McAllister et al. 
1998) 
 
In a follow-up study, McAllister et al (2000) showed that epidermis permeability to 
calcein, fluorescently-tagged bovine serum albumin (BSA) and nanospheres can be 
increased up to 10,000 fold after treatment with silicon microneedles.  In addition, 
Kaushik et al. (2001) tested the pain level associating with the insertion of silicon 
microneedle arrays into human skin in vivo.   The study showed that the microneedles 
caused an insignificant amount of pain compared to conventional hypodermic needle 
insertion, and no subjects reported any adverse reactions.  In a separate study, Chabri et al. 
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(2004) inserted silicon microneedles into human epidermal sheets in vitro and delivered 
pDNA (LPD), a nonviral gene therapy vector, into the tissue. 
 
2.2.1.3 Metal microneedles 
 Metal is considered a better alternative material for microneedles since it has good 
mechanical strength, is relatively inexpensive and can be fabricated with ease. Solid, 
stainless steel microneedles can be made by a laser-cutting technique.  The resulting 
needle structures are bent out of the sheet, and electropolished.  The needles can be in 
either single microneedles or multi-needle array form. Martanto et al (2004) used 
stainless steel solid microneedles to deliver insulin to diabetic hairless rats in vivo.  
Needle arrays were inserted into the rat skin using a high-velocity injector.  A solution of 
insulin was placed on top of the microneedle arrays and left in place for 4 h.  Over this 
time period, blood glucose level steadily decreased by as much as 80% compared to the 





Figure 2.2.4. Solid stainless steel microneedle arrays used in an insulin delivery test using 
diabetic rats in vivo (Martanto, Davis et al. 2004). 
 
 
 Recently, a new delivery method associated with metal microneedles was 
developed.  Using a formulated coating solution, different sized molecular compounds 
ranging from micro- (sodium fluorescein, sulforhodamine, etc.) to macro- (proteins, DNA, 
etc.) can be coated onto the shafts of either single metal microneedles or multi-arrays of 
microneedles as shown in Figure 2.2.5 (Gill and Prausnitz 2006).  After insertion into the 
tissue, the naturally hydrophilic-coating instantly dissolves off the microneedle shafts and 







Figure 2.2.5.  Images of coated solid metal microneedles.  (A) shows a fluorescent image 
of a single microneedle coated with sodium  fluorescein, NaFl, and (B) shows an multi-





2.2.2 Hollow microneedles 
 
 Skin permeability can be dramatically increased by the holes created from solid 
microneedles insertions.  However, it is still necessary to have more controlled and 
reproducible transport pathways to delivery drugs into the tissue.  The fabrication of 
hollow microneedles that allow transport through the hollow shaft of the needle was 
based on this need.  The inclusion of a hollow lumen in a microneedle structure expands 
its capabilities dramatically and can offer the following advantages:  the ability to deliver 
larger molecules and particles; deliver material in a convective transport fashion (for 
example, pressure-driven flow) instead of passive diffusion; and minimize the cross-
contamination of the deliverables and its surrounding.  A variety of hollow microneedles 
has been fabricated and has demonstrated success in transdermal drug delivery. 
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2.2.2.1 Silicon hollow microneedles 
 The most logical technique for the inclusion of a lumen in the silicon spikes 
presented is the addition of an etching step to form a fluidic channel using standard 
photolithography and isotropic-anisotropic etching combination (Stoeber and Liepmann 
2002).  The fabrication steps include coating silicon dioxide on a silicon wafer, patterning 
the backside of the wafer and etching through the wafer stopping on the upper oxide layer 
to define the needle lumen.  Silicon nitride was then deposited, and a larger circular mask 
was patterned on the front side and underetched to create the tapering effect of the 
microneedle.  After both silicon dioxide and silicon nitride layers were removed, 
symmetrical and asymmetrical needle structures can be achieved by adjusting the relative 
position of the isotropic and anisotropic etching axis.  The hollow silicon structures have 
been created in three-dimensional arrays out of the substrate plane.  An extension of the 
solid pyramids of Hashmi was found to effectively withdraw blood through the lumen by 





Figure 2.2.6. Arrays of symmetric silicon hollow microneedles used in fluid injection 
experiments (Stoeber and Liepmann 2000). 
 
Also, an extension to the solid silicon spikes of Henry was found to deliver both larger 
particles (700 nm Nanospheres) and dye to chicken thighs under pressure driven flow 





Figure 2.2.7.  Arrays of hollow silicon microneedles used for transdermal liquid transport 
(Gardnier, Berenschot et al. 2002) 
 
 
2.2.2.2 Metal hollow microneedles 
 Hollow metal microneedles can be creating using laser micromachining (Davis 
2003).  Microneedles with straight walls (i.e. that is not tapered) are fabricated using 
molds with cylindrical holes created either by reactive ion etching (RIE) through silicon 
wafers or lithographically defining holes in SU-8 photoresist polymer.  A thin coating of 
metal was then electrodeposited onto the molds to produce the desired microneedles.  
Tapered hollow needle was fabricated either by obtaining a mold from a silicon master or 
laser drilling tapered holes into polymer sheets, followed by electrodeposition of a thin 
metal coating onto the mold.  Davis et al. (2004) have demonstrated the insertion test 




Figure 2.2.8.  An array of hollow, metallic microneedles used for skin insertion test 
(Davis 2003).  
 
 
The study reported that less insertion force was required since the interfacial area of the 
needle that is in contact with the skin was reduced.  Additionally, these microneedles 
offered stronger mechanical stability.  As a follow-up study, Martanto et al (2004) 
delivered insulin into hairless, diabetic rats in vivo using these hollow microneedle arrays.  
After 4 hours of delivery, the blood glucose levels of the rats were reduced to 47% of 
their original value, which indicated the successful transdermal delivery.  
 
2.2.2.3 Glass hollow microneedles 
Hollow, glass microneedles can be quickly produced with different geometric 
parameters for small-laboratory use.  These needles are physically capable of insertion 
into the tissue without breaking, having a larger drug loading dose and permitting 
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visualization of the deliverables.  Thin glass capillaries were placed within a micropipette 
puller, and could have either a blunt or a beveled tip, which allowed ease of needle 
insertion into the tissue.  Coupling with an insertion apparatus, the insertion depth of the 
needle into the tissue can be controlled precisely.   
McAllister et al. (2003) used single glass microneedles inserted into the skin of 
diabetic hairless rats in vivo to deliver insulin during a 30-min infusion period.  The 
needles had a tip radius of 60 µm and were inserted into the tissue of a depth of 500-800 
µm.  The results indicated an up to 70% drop in blood glucose level over a 5-h period 
after the insulin was administered.  Using single, beveled-tip microneedles, Martanto et 
al. (2006) examined the effect of different experimental parameters on microinfusion 
through hollow glass microneedles into human skin in vitro.  The study reported that 
partial retraction of the needle within the tissue increased delivery flow rate 10-fold 
compared to that without retraction.  Infusion rates could also be increased at a greater 
insertion depth, a larger infusion pressure, a beveled-tip instead of a blunt tip and the 
addition of hyaluronidase enzyme. 
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Figure 2.2.9.  A single, beveled-tip, hollow glass microneedle used in microinfusion 





2.2.3 Other types of microneedles 
 
Besides solid and hollow microneedles, various other types of microneedles were 
fabricated using different materials such as biodegradable polymers, polysilicon and 
sugar with additional functionalities.  Because of their biocompatible nature with the 
tissue, biodegradable polymer microneedles were developed (Park, Allen et al. 2006).  
These needles were fabricated by initially making master structures using lithography-
based methods, creating inverse structures from the master molds, and finally producing 
replicate microneedles by melting biodegradable polymer formulations (i.e. poly-lactic 
acid, PLA, or poly-lactic-co-glycolic acid, PLGA) into the molds.  The resulting 
microneedles can be loaded with molecules, drugs, DNA or proteins.  Unlike solid and 
hollow microneedles, polymer microneedles themselves serve as the drug implants after 
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insertion into the tissue.  Park et al. (2006) inserted the microneedles loaded with calcein 
or bovine serum albumin (BSA) into full thickness human cadaver skin.  Strong images 
of the fluorescent model drugs were detected over 200 µm deep from the skin surface.  
Additionally, the in vitro release profiles of calcein and BSA ranged from hours to 
months depending on the formulations. 





Figure 2.2.10.  Solid biodegradable polymer microneedles with calcein encapsulated at 
the needle tips used for in vitro transdermal insertion test (Park, Allen et al. 2006). 
 
Ito et al. (2006) prepared microneedles encapsulated with erythropoietin (EPO) for 
percutaneous administration of EPO into mice in vivo.  Under room temperature, EPO 
solution was added to high concentration of polymer solution (dextrin, chondroitin sulfate 
or albumin) and microneedle were prepared by forming thread with polypropylene tips.  
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The results suggested the effectiveness and usefulness of microneedles for administration 
of EPO. 
 Microneedles made out of maltose mixed with ascorbate were developed for 
transdermal delivery of drugs (Miyano, Tobinaga et al. 2005).  The lengths of these 
needles were ranging from 150 µm to 2 mm.  A clinical experiment was performed to test 
the biosafety and basic tolerance of these microneedles.  The tests showed the sugar-
based microneedles spontaneously dissolved and released ascorbate into epidermis and 
dermis of human skin.  No dermatological problems were reported. 
 
    
Figure 2.2.11. An array of 500 µm microneedles made out of maltose and used in 
transdermal insertion test (Miyano, Tobinaga et al. 2005) 
 
Aside from being a drug delivery tool, microneedles can also be used as a 
biosensor.  One major reason for loss of biosensor activity is through the settling of large 
molecular weight compounds onto the sensor and affecting senor signal stability.  A 
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microdialysis microneedle is fabricated that is capable of excluding large MW 
compounds (Zahn, Trebotich et al. 2005).   
 
Figure 2.2.12.  A microdialysis microneedle next to a dime for size comparison (Zahn, 
Trebotich et al. 2005). 
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3 MATERIALS and METHODS 
3.1 Lateral diffusion within human sclera 
3.1.1 Experimental methods 
3.1.1.1 Lateral diffusion measurements 
 The lateral diffusion profile of a model drug, sulforhodamine (558 Da; Molecular 
Probes, Eugene, OR), was measured through human cadaver sclera using 
spectrofluorometry.  Human sclera was obtained from the Georgia Eye Bank (Atlanta, 
GA) and stored in a moist container for 2 – 5 days at 4 oC.  Adherent tissues associated 
with the retina, choroid and episclera were gently removed with cotton swabs. Strips of 
full-thickness sclera measuring 10 – 15 mm in length and 3 – 5 mm in width were cut 
from the globes using surgical scissors and razor blades.  
 In this study, we used human cadaver sclera, which has the advantage of being human 
tissue and enabling better control over the experimental system through the in vitro 
environment. Although an in vivo animal study would provide an improved physiological 
environment, this study focused on the process of diffusion within the sclera, which is 
governed largely by the non-living collagen and extracellular matrix structures, and did 
not address the effects of, for example, blood flow or other active processes.   
A glass vial was filled with 1 ml of donor solution containing 9.0 x 10-5 M 
sulforhodamine in Balanced Salt Solution (BSS; Alcon Laboratories, Ft. Worth, TX). A 
scleral strip was suspended vertically in the glass vial such that the lower 3 mm of the 








Figure 3.1.  Experimental apparatus to measure lateral diffusion profiles within human 
cadaver sclera.  A scleral strip was suspended vertically in a glass vial with the lower end 
of the tissue submerged in a donor solution of sulforhodamine. At different time points, 
the tissue was removed, rinsed, snap-frozen, sectioned, and analyzed by calibrated 
spectrofluorometry to determine sulforhodamine concentration in the sclera as a function 
of time and position.   
 
The vial was then capped and sealed with parafilm to maintain scleral hydration and 
placed in a 37 0C water bath, although some tissue dehydration probably still occurred.  
After a designated experimental period (4, 24, 48, 72 or 168 h), the scleral strip was 
removed from the vial, rinsed with BSS, placed into a sample block containing OCT 
freezing-agent (Sakura Finetechnical, Tokyo, Japan) and snap-frozen using liquid 
nitrogen.   
The scleral tissue was sectioned into 50µm thick pieces using a cryostat microtome 
(Richard Allan Scientific, Kalamazoo, MI).  Every 15 consecutive pieces (750 µm) were 
collected as one sample. To account for the difference in scleral thickness, the first piece 
from each sample was examined by brightfield microscopy to determine its cross-
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sectional area, which was assumed to be representative of the entire sample. The 
remaining 14 pieces from each sample were placed into a test tube containing 2 ml BSS 
and allowed to incubate in the dark at 4 oC for 12 h to extract the sulforhodamine from 
the tissue sections.   
The solution in each tube was then placed into a cuvette (Vcuvette = 1.8 ml) to 
determine its sulforhodamine concentration by calibrated spectrofluorometry (Photon 
Technology International, Lawrenceville, NJ) at an excitation wavelength of 565 nm and 
emission spectra collected at 580 – 620 nm. The sulforhodamine concentration within the 




VCC ⋅=    (1) 
where Ccuvette is the sulforhodamine concentration in the cuvette, determined by 
spectrofluorimetry, and Vtissue is the volume of each tissue sample, which is equal to the 
measured cross-sectional area multiplied by the total thickness of 14 tissue pieces 
analyzed per section (i.e. 700 µm).  In this way, drug concentration within the tissue was 
determined as a function of distance along the sclera at each time point. 
 
3.1.1.2 Trans-scleral diffusion measurements 
 Sulforhodamine diffusion was also measured across the sclera using a flow-through 








Figure 3.2. Schematic diagram of the perfusion chamber used for measuring trans-scleral 
permeability under simulated intraocular pressure (Rudnick, Noonan et al. 1999).   Sclera 
is mounted in a horizontal perfusion setup while an intraocular pressure is simulated to 
create an outflow.  The compound to be tested is added to the donor chamber.   The 
receiver chamber has a continual flow and is magnetically stirred using a stir bar 
 
 
Following the procedure described previously (Rudnick, Noonan et al. 1999), scleral 
disks of 10 – 15 mm in diameter were excised from human globes and mounted in two-
compartment perfusion chambers. A 300 µl depot of 9.0 x 10-5 M sulforhodamine donor 
solution was added to the episcleral surface while perfusing BSS across the choroidal 
side.  Every 1 h, a fraction containing 2 ml of the perfusate was collected over a 24 h 
period and its fluorescence concentration was measured by spectrofluorimetry. From 







=    (2) 
where d is scleral thickness (0.6 mm) (Olsen, Edelhauser et al. 1995), A is the scleral 
surface area exposed to donor solution (0.37 cm2), ∆t is sampling time (1 h) and Cdonor is 
the sulforhodamine concentration in the donor solution, which was initially at 9.0 x 10-5 
M and decreased over time; this effect was accounted for by correcting Cdonor in the 
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calculation using Eq. 2. The trans-scleral permeability coefficient can be obtained by 
dividing the transverse diffusivity by scleral thickness (Edwards and Prausnitz 1998). 
 
3.1.1.3 Sclera-to-saline distribution coefficient 
An additional experiment was performed to determine the sclera-to-saline 
distribution coefficient to examine possible binding between sulforhodamine and scleral 
tissue. A full-thickness scleral strip was submerged in a 9.0 x 10-5 M sulforhodamine 
donor solution for 24 h.  After removing the tissue and rinsing with BSS, the tissue was 
sectioned into 50-µm thick pieces using a cryostat.  All tissue pieces were collected and 
incubated in 20 ml of BSS. The sulforhodamine concentration in the BSS was measured 
over time using spectrofluorometry until it reached a constant value (after ~1 h). 
Assuming 100% sulforhodamine extraction efficiency, the sclera-to-saline distribution 





K =      (3)  
where Csclera is the concentration in the sclera determined by extraction, and Cbath is the 
original concentration of the donor solution (9.0 x 10-5 M).   
 
3.1.2 Theoretical modeling 
A theoretical model was developed to predict the concentration of sulforhodamine 
as a function of both time and distance during lateral diffusion within human sclera. A 
one-dimensional model was justified by the geometry of the experimental set-up, which 
was symmetric in both of the horizontal dimensions of the scleral strip and only provided 
a concentration-gradient driving force for diffusion in the vertical direction (Fig. 1). We 
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further recognized that the sulforhodamine could be present within sclera in two forms: 
(i) free sulforhodamine that can diffuse and (ii) bound sulforhodamine immobilized at 
binding sites in the scleral tissue. Previous studies have suggested that compounds 
structurally similar to sulforhodamine bind within sclera (Prausnitz, Edwards et al. 1998).   
Transient, one-dimensional diffusion with binding in a semi-infinite slab can be 

















−=    (5) 
where Cfree is the free sulforhodamine concentration in the sclera, Cbound is the bound 
sulforhodamine concentration in the sclera, k1 is the binding rate constant, Dlat is the 
effective lateral diffusivity of free sulforhodamine in the sclera, x is the lateral position in 





K =       (6) 
  To evaluate bound versus free sulforhodamine in the sclera, the sclera-to-saline 











==     (7) 
Because the liquid phase of sclera is composed of saline of similar composition to that of 





K 111 +=+=     (8) 
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Using Eq. 8, as well as the assumption that sulforhodamine binding in the sclera is at 
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=     (10) 
To solve Eq. 10, the initial and boundary conditions are: 
          Cfree(x,0) = 0 
Cfree(0, t) = Cdonor ּ KD    (11) 
          Cfree(z, t) = 0 
where z is the length of the scleral strip above the donor solution. Solving Eq. 10 subject 
to the conditions in Eq. 11, yields the final expression for sulforhodamine concentration 















−⋅⋅=   (12) 
where erf is the error function. 
 
3.1.3 Statistical analysis 
 Mean absolute percent error (MAPE) was used to statistically analyze the 
difference between theoretical predictions and experimental data.  MAPE is calculated by 
averaging the percentage difference between fitted (predicted) values and experimental 








MAPE theor    (13) 
where Cexp is the experimentally measured concentration, Ctheor is the theoretically 
predicted concentration, and n is the number of measurements. 
 
3.2. Ocular drug delivery using coated solid microneedles 
3.2.1 Microneedle fabrication 
Single solid metal microneedles were fabricated using an infrared laser 
(Resonetics Maestro) to cut needle structures from stainless steel sheets (SS 304, 75 µm 
thick; McMaster-Carr, Atlanta, GA).  The shape and orientation of microneedle structures 
were initially drafted in a CAD file (AutoCAD; Autodesk, Cupertino, CA), which was 
converted to the file type required by the laser control software (Oregon Microsystems, 
Beaverton, OR).  The laser beam traced the desired pattern of the needle that ablated the 
metal sheet and created the microneedles within the plane of the sheet. 
To deburr and sharpen the microneedle edges, electropolishing was applied after 
laser cutting.  The metal sheet with needles on it was cleaned using hot soapy water 
(Alconox, White Plains, NY) and rinsed with DI water.  Each needle was then manually 
bent out of the sheet at 90o.  The sheet was then placed into a 1:3:6 v/v mixture of water, 
phosphoric acid and glycerin (Fisher Scientific) to remove debris.  The mixture was 
maintained at 70 oC and stirred at 150 rpm using a magnetic stirring bar, while the sample 
sheet was manually agitated during the electropolishing process.  After 20 minutes of 
polishing, the sheet was rinsed in DI water for 10 seconds followed by another 10 
seconds each in 20% nitric acid (VWR, West Chester, PA) and in hot water.  This rinsing 
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cycle was repeated 3 times.  After electropolishing, each microneedle was manually 
detached from the metal sheet using a pair of scissors.   
 
3.2.2 Microneedle coating 
Using a previously described coating method (Gill and Prausnitz 2006), single, 
solid stainless steel microneedles could be coated with different molecular compounds in 
a formulated coating solution.  The coating dose onto each microneedle is dependent on 
various factors, including the composition of coating solution, the number of needle dips 
into the solution and the duration of leaving the needle within the solution.    Each single 
microneedle was mounted individually onto a micropositioner in a manually assembled 
coating apparatus, and dip-coated horizontally into a large-orifice pipette tip containing 
the coating solution.  Each dipping step lasted for 3 seconds and the coating procedure 
was repeated 5 times for each microneedle coating. The entire procedure was performed 
under a stereomicroscope.  In this study, the coating solution was comprised of 10% (w/v) 
poly-vinyl-pyrrolidone (PVP) (1300 kDa; Sigma-Aldrich, St. Louis, MD) and a coating 
compound.  For in vitro experiments, the coating compound was 0.05% (w/v) 
sulforhodamine (558 Da; Molecular Probes, Eugene, OR), 1% fluorescein-labeled bovine 
serum albumin (Molecular Probes) and 0.05% gWizTM luciferase plasmid DNA (6732 
base pairs, Aldevron, Fargo, ND).  DNA was made fluorescent by incubating with 
YOYO-3 (Molecular Probes) at a dye:base pair ratio of 1:4 for 1 h at room temperature in 
the dark.  For in vivo experiments, the coating compounds were 0.5% (w/v) sodium 
fluorescein, NaFl, (376 Da; Sigma-Aldrich, St. Louis, MO) and 10% (w/v) pilocarpine 
hydrochloride (243 Da; Sigma-Aldrich).  
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To determine the dose of compound coated onto the microneedle, coated 
microneedles were placed into cuvettes containing 2 ml of phosphate-buffered saline, 
PBS, (Mediatech, Inc., Hernodon, VA), which allowed the coating solution to dissolve 
off the needle shaft.  The compound concentration in each cuvette was then measured 
using either spectrofluorometry (Photon Technology International, Lawrenceville, NJ) for 
fluorescein-labeled molecules or UV spectrometry (Molecular Devices, Sunnyvale, CA) 
for pilocarpine molecules.  The coating dose was then calculated as following: 
Coating dosage = Ccuvette * Vcuvette * MWcompound  (14) 
where Ccuvette is the measured molar compound concentration in the cuvette, MW is the 
molecular weight of the compound and Vcuvette is the volume of PBS solution in the 
cuvette. 
 
3.2.3 In vitro coated microneedle insertion 
 Human sclera was obtained from the Georgia Eye Bank (Atlanta, GA).  
Pieces of sclera tissue (0.7 x 0.7 cm) were cut from scleral globe using surgical scissors, 
rinsed with water, and adherent tissues associated with the retina, choroid and episclera 
were removed with cotton swab.  The scleral tissue was placed on top of a hemi-sphere 
surface (0.6 cm in radius), which simulated the curving ocular shape.  Even though solid 
metal microneedles showed successes in previous transdermal insertion tests, they have 
never been tested in ocular tissues.  To examine whether solid microneedles are strong 
enough to penetrate into the sclera, single non-coated microneedles were manually 
pierced into human cadaver sclera.  The insertion site was then stained with blue tissue 
dye (tissue marking Dye; Shandon, Pittsburg, PA) for visual examination.  In the later 
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phase, single sulforhodamine-coated microneedles were manually pierced into the sclera.  
The needles were left within the tissue for 20 sec after insertion to allow the coating 
solution to dissolve off.  Upon needle removal, the excess sclera tissues around the 
insertion site were trimmed away using a surgical blade.  The resulting tissue pieces were 
placed in sample blocks containing OCT freezing-agent (Sakura Finetechnical, Tokyo, 
Japan) and snap-frozen using liquid nitrogen.  Each scleral tissue was sectioned into 10-
µm thick pieces using a cryostat microtome (Richard Allan Scientific, Kalamazoo, MI).  
Histological pieces were collected onto glass slides, and examined using a fluorescent 
microscope (Olympus X70). 
 
3.2.4 In vivo coated microneedle insertion 
3.2.4.1 Fluorescein-coated microneedle 
 A single New Zealand white rabbit (1.8-2.2 kg) was used in this study.  The 
animal was kept in the cage and fed with food and water on a daily basis.  Prior to 
microneedle insertion, the animal was anesthetized using intramuscular injection of 5 
mg/kg xylazine (Butler, Columbus, OH) and 35 mg/kg ketamine (Bedford laboratories, 
Bedford, OH).  A single NaFl-coated solid microneedle (500 µm in length, 45o in tip 
angle) coated with 0.3 µg of NaFl was manually inserted half-way into the upper region 
of the rabbit cornea, to prevent possible leakage of the aqueous solution from the rabbit 
eye.  The needle was held steady within the cornea tissue for 2 minutes before removal.  
The fluorescein concentration in the anterior part (cornea, aqueous humor and lens) of the 
eye was measured periodically using a fluorometer (Ocumetrics, Mountain View, CA) at 
0, 0.5, 1, 2, 3, 4, 5, 6 and 24 hours after insertion.  This fluorometer delivered a 
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specifically focused excitation beam of blue light using an optic head into the ocular 
cavity and then received the resulting fluorescent green light and directed it into a 
photodetector.  By changing the focal plane every 0.25 mm, sequential readings of the 
fluorescein concentration were obtained along an axis from the lens in the eye to a 
position anterior to the cornea.   
The fluorescein concentration in the non-inserted eye was also monitored as the 
negative control.  The animal was brought back to the cage, given a 24 h recovery period, 
and same experiment was applied to the other eye.  As the positive control, a drop of 
NaFl solution that used for coating was applied topically to the rabbit eye, and the 
fluorescein concentration in the eye was measured over same time periods.   
 
3.2.4.2 Theoretical estimation of microneedle delivery efficiency 
 To estimate the delivery efficiency by a single, fluorescein-coated microneedle in 
the in vivo animal study, a mass balance of fluorescein in the aqueous humor of the rabbit 
eye was performed as shown in Eqn. (15): 
daccumulateoutin MMM +=     (15) 
where Min is the mass inflow rate of fluorescein, Mout is the mass outflow rate of 
fluorescein, and Maccumulated is the mass of fluorescein accumulated within the aqueous 
humor over each time increment.  Assuming the volumetric fluorescein outflow rate is as 
same as the aqueous humor production rate, Mout can be calculated as: 
sfluoout vCM *=      (16) 
where Cfluo is the fluorescein concentration leaving the aqueous humor, which is 
equivalent to the experimental measurement assuming the fluorescein concentration is 
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uniform throughout the aqueous humor, and vs is the aqueous humor production rate, 
which is reported as 0.0042 – 0.0045 ml/min in the rabbit eye (Fatt and Wissman 1992).  











  (17) 
where ∆Cfluo is the change of fluorescein concentration in the aqueous humor between 
two time points, V is the aqueous humor volume, which is about 0.3 ml in the rabbit eye 
(Girgis, Reed et al. 2005) and ∆t is the time change. 
By substituting Eqn. (16) and (17) into Eqn (15), the mass in-flow rate of fluorescein, Min, 
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in which i is the total number of measurement points, n is the corresponding 
measurement point and t is the time of the measurement. 
 
3.2.4.3 Pilocarpine-coated microneedle 
To assess whether microneedle can deliver drug molecules into the eye, we coated 
microneedles with a commercially used drug, pilocarpine, which causes pupil contraction 
and is used to treat glaucoma (Lee and Higginbotham 2005; Uva, Longo et al. 2006).  All 
the insertion experiments were carried out in a bright room with consistent light intensity.  
After anesthetizing the rabbit, five single pilocarpine-coated solid microneedles (500 µm 
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in length, 45o in tip angle, each needled coated with 1.1 ± 0.5 µg pilocarpine) were 
inserted halfway into the rabbit cornea individually.  The needles were spaced radially 
with an even pattern of spacing between the insertion points.  Each needle was left within 
the cornea 20 seconds before removal.  The diameter of the rabbit pupil was then 
measured every minute for half an hour, continued on an hourly basis for 4 hours after 
microneedle insertion, and the corresponding image was captured with a digital camera 
(Canon U.S.A. Inc.).  The pupil sizes of the other eye were measured at the same time 
points as the untreated control.  As another control, a drop of pilocarpine (Sigma-Aldrich) 
solution at equivalent dose to the microneedle coating was topically applied to the eye.  
In addition, a positive control consisted of one drop of 1% ophthalmic pilocarpine 
solution (Falcon Pharmaceuticals, Ltd., Fort Worth, Texas) applied to the rabbit eye.    
 
3.2.5 Safety examinations 
 Single uncoated solid microneedles were inserted into the rabbit cornea after the 
animal was anesthetized.  A slit-lamp examination was used to examine the microneedle 
insertion site.  Before each measurement, a droplet of fluorescein solution (0.5% w/v) 
was applied topically to the insertion site of the eye, which helped to identify the 
insertion gap.  The rabbit eye was examined for cell and flare responses for any possible 






3.3. Microinfusion using hollow microneedles 
3.3.1 Tissue preparation 
 
Human cadaver eyes were obtained from the Georgia Eye Bank (Atlanta, GA) 
and stored in moist container at 4 oC for 2-7 days before use.  A piece of sclera tissue (1 x 
1 cm) was cut from the globe using surgical scissors.  Adherent tissues associated with 
the retina, choroid and episclera were gently removed with cotton swabs.  The sclera 
tissue was soaked in water for 5 min prior to each infusion experiment to retain its 
physiological hydration level.   The scleral piece was placed onto a hemi-spherical 
surface (0.6 cm in radius) that was obtained by cutting off the end of a polystyrene round-
bottom flow tube (BD FalconTM, Bedford, MA), which mimics the ocular curvature.   
 
3.3.2 Microneedle fabrication 
Single, hollow, glass microneedles were used in this study.  Using a previously 
described method (Martanto, Moore et al. 2006), these microneedles were fabricated 
using a micropipette puller.  Fire-polished borosilicate glass pipettes (o.d. 1.5 mm, i.d. 
0.86 mm, B150-86-15, Sutter Instrument Co., Novato, CA) were pulled using a 
micropipette puller (P-97, Sutter Instrument) and detached into two halves at desired 
settings.  These blunt-tip microneedles were then beveled at a setting of 20o tip angle 
using a glass grinder (BV-10, Sutter Instrument).  Each needle was connected to a 3 ml 
syringe by a small piece of tubing, dipped into a chromic acid bath (Mallinckrodt, 
Hazelwood, MO) while blowing air through the needle shaft for 15 sec, and followed by 
the same procedures using DI water and acetone (J.T. Baker, Phillipsburg, NJ) for 15 sec 
each.  The resulting microneedles were examined using bright field microscopy (Leica 
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DC 300; Leica Microsystems, Bannockburn, IL) and image analysis (Image Pro Plus, 
Media Cybernetics, Silver Spring, MD).   
 
3.3.3 Experimental apparatus 
A 1-ml glass syringe (Gastight Syringe, Hamilton Company, Reno, NV) was used 
as the delivering solution reservoir.  One end of the syringe was connected to a high-
pressure CO2 tank (Airgas, Radnor, PA), and the other end was connected to a 2.1-mm-
i.d. metal tubing line, which was connected to the end of a glass microneedle by a 
flexible tube linker.  A pressure regulator (Two-Stage Regulator, Fisher Scientific, 
Hampton, NH) was used to adjust pressure during the delivery.  A custom-made device 
(Wang, Cornwell et al. 2005) was designed to hold the needle.  In a controllable fashion, 
the microneedles could be inserted into and retracted within the scleral tissue by rotations 
(i.e., 1 full rotation equals 1440 µm in microneedle displacement).  The entire assembly 
was held by a stainless-steel adapter mounted to a Z-stage (Graduated Knob Unislide, 
Velmex, Bloomfield, NY) to control the vertical motions of the microneedle holder.   
 
3.3.4 Infusion of sulforhodamine solution 
Sulforhodamine (558 Da; Molecular Probes, Eugene, OR), which serves as a 
model drug and a visual marker for fluid flow, was added to phosphate buffered saline 
(PBS) to make a 1 x 10-3 M sulforhodamine solution to be delivered into the human 
sclera tissue.   The solution was loaded into the glass syringe of the apparatus using a 5-
ml syringe.  Single, bevel-tipped, microneedles were then inserted and delivered 
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sulforhodamine solution into human cadaver sclera at a constant pressure (5, 10, 15, 20 
and 25 psi).   
In the human eye, the sclera is relatively thick near the limbus (0.53 ± 0.14 mm); 
it thins at the equator (0.39 ± 0.17 mm) and becomes substantially thicker near the optic 
nerve (0.9 to 1.0 mm) (Olsen, Aaberg et al. 1998).  To examine the effect of scleral 
thickness on volume delivery, the sclera was divided into 3 different regions around the 
globe: front (near the limbus), middle (at the equator), and back (near the optic nerve).  
The microneedles were initially inserted into the tissue at a depth of 700 – 1080 µm, and 
retracted out of the tissue in increments of 60 µm.  Throughout the experiments, the 
volumetric delivery of sulforhodamine solution was monitored by the movement of the 
gas-fluid meniscus in the glass syringe, and the differences were recorded between each 
retraction.  The infusion was immediately stopped when a retraction caused leakage of 
sulforhodamine solution to be first seen on the surface of the tissue.   
 
3.3.5 Delivery of nanoparticles 
To determine if hollow microneedles can deliver nanoparticles into the sclera, 
nanospheres were added to 1 ml PBS solutions at solid contents of 0.5, 1, 5 and 10 wt %, 
and delivered into the sclera at 15 psi.  Provided courtesy of Dr. Uday Kompella 
(University of Nebraska), these nanospheres, made out of poly-lactic acid (PLA), had an 
effective diameter of 278 ± 13 nm and encapsulated Nile Red within the particle.  A 
previous study reported that only 0.4% Nile Red was released from PLA nanoparticles 
over 28 days (Bourges, Gautier et al. 2003).  The particles were dispersed in PBS solution 
and vortexed for further suspension. Due to the limited quantity of nanospheres available, 
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each microneedle was then preloaded with just 20 µl nanosphere solution, inserted into 
each region on the sclera and delivered into the tissue using same insertion and retraction 
procedures described above for sulforhodamine solution infusion.   
 
3.3.6 Delivery of microparticles 
Solid latex, fluorescein-labeled microspheres (1.0 micron in diameter, 
Polysciences Inc., Warrington, PA) were added to 1 ml PBS solutions at solid contents of 
0.3, 1.3 and 2.6 wt% for infusion delivery.  A drop of 5 µl polyoxyethylenesorbitan 
monooleate (Tween 80, Sigma Chemical Co., St. Louis, MO) was then added to each 
solution to reduce the surface tension and enhance the microparticle stability within the 
solution.  The mixture was then vortexed and ultrasonicated to ensure the microspheres 
were suspended without clumping within the solution.  Single hollow glass microneedles, 
preloaded with 20 µl microsphere solution, were inserted into each region on human 
sclera tissue for delivery as described above.   
 
3.3.7 Effect of collagenase and hyaluronidase 
Two types of experiments were performed to examine the effect of hyaluronidase, 
an enzyme known to break down the glycosaminoglycans (GAGs) in the scleral 
extracellular matrixes, on scleral delivery using hollow microneedles: first, the scleral 
tissue was soaked in a 200 U/ml hyaluronidase solution (Vitrase, 200 U/ml, ISTA 
Pharmaceuticals, Irvine, CA) for 1 h prior to microneedle injection and later infusion 
experiments were performed; and second, hyluronidase solution was mixed with the 
injectable solution and delivered into the sclera by hollow microneedles.  Collagenase 
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type I (Sigma Aldrich, St. Louis, MO), which is known to break down type I collagen 
fibers, was also tested for possible enhancement of particle delivery within the sclera.  
Same experimental procedures were carried out. 
 
3.3.8 Histological and microscopic image analysis 
After each microneedle infusion experiment, the backside of each scleral tissue 
was examined under bright-field microscope (Leica DC 300) to ensure that no solution 
leakage occurred on the back of the tissue.  To visualize the microneedle penetration 
pathways and the distribution of solution within the sclera, histology was used.  Scleral 
tissues after microneedle infusions were immediately rinsed with water to wash off the 
residue solution on the tissue surface.  Tissues were then placed into sample blocks 
containing freezing agent (OCT; Sakura Finetechnical, Tokyo, Japan) individually, and 
snap frozen with liquid nitrogen.  Each tissue sample was sectioned into 10 µm thick 
pieces using a cryostat microtome (Richard Allan Scientific, Kalmazoo, MI) and was 
collected into consecutive sections onto glass slides.  Each histological section was then 
examined using both bright-field (Leica DC 300) and fluorescence microscopy (Eclipse 
E600W, Nikon, Melville, NY). 
 
3.3.9 Statistical Analysis 
 Replicates of microneedle infusion experiments were performed at each different 
condition (scleral position and pressure), from which the mean and standard deviation 
were calculated.  A one-way analysis of variance (ANOVA, α = 0.05) was used to 
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examine the impact of scleral position and pressure on the dose delivery.  In all cases, a 






  4 RESULTS   
4.1 Lateral diffusion within human sclera 
4.1.1 Introduction 
 Targeted administration of drugs to the posterior segment of the eye remains a 
significant challenge in ocular drug delivery.  Current treatment strategies include 
systemic delivery, by oral or parenteral routes, and local delivery using topical drops, 
subconjunctival and peribulbar injections, intravitreal injections, and implants (Lang 
1995; Geroski and Edelhauser 2000).  However, none of these approaches provide fully 
satisfactory ocular delivery to the posterior part of the eye. 
  Systemic delivery is often accompanied by side effects because of the high drug 
doses needed to reach the target tissues within the eye.  Topical drops through cornea 
generally cannot achieve adequate drug concentrations in the posterior segment due to 
slow diffusion across the cornea to the back of the eye, blinking and counterproductive 
convection of tear fluid and aqueous humor (Lang 1995; Tasman 1995). While 
intraocular injection and implants can provide delivery targeted to the posterior segment, 
they can lead to complications such as retinal detachment, hemorrhage, endophthalmitis 
and cataract, especially when repeated injections are required (Tasman 1995; Maurice 
2001).  
  Because of these limitations, there is growing interest in drug delivery across the 
sclera, which avoids the complications associated with penetrating the globe and the 
diffusional barrier of the cornea (Geroski and Edelhauser 2000).  The sclera’s large 
surface area, which averages 17 cm2 on the human eye (Olsen, Aaberg et al. 1998), is 
approximately 20-fold larger than cornea.  Moreover, sclera is much more permeable, 
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especially to large and hydrophilic drugs (Maurice and Polgar 1977; Olsen, Edelhauser et 
al. 1995).  Conventional subconjunctival and peribulbar injections provide access to the 
trans-scleral route. Novel delivery systems, involving implants, gels and patches applied 
to the scleral surface and intrascleral injections are being developed to enable extended-
release and better-targeted drug delivery via the sclera (Geroski and Edelhauser 2000). 
  Motivated by these opportunities, a number of studies have examined rates of 
diffusion across the sclera as a function of molecular size and other parameters (Prausnitz, 
Edwards et al. 1998; Ambati, Canakis et al. 2000; Cruysberg, Nuijts et al. 2002; Gilbert, 
Simpson et al. 2003; Mora, Eperon et al. 2005). However, little attention has been given 
to diffusion within the sclera in the lateral direction parallel to the scleral surface, which 
could affect drug distribution caused by lateral spread of drug released, for example, from 
an extraocular implant or intrascleral injection. The non-isotropic architecture of collagen 
lamellae and other features of scleral microanatomy (Fatt and Weissman 1992) suggest 
that lateral diffusion may behave differently from trans-scleral diffusion.  
  To address this issue, this study presents the first experimental measurements of 
lateral diffusion within the sclera using sulforhodamine as a model drug and provides a 
theoretical model that predicts the diffusion profile as a function of both time and 
distance along the sclera.  Lateral diffusivity values are also compared to transverse 
diffusivity across sclera to identify possible differences.   
 
4.1.2. Imaging lateral diffusion within the sclera 
  An initial experiment was carried out to provide visual images showing the 
progression of sulforhodamine diffusion along the sclera as a function of time and 
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position.  Fig. 4.1 shows representative cross-sectional views of sclera frozen after 24 h 
of sulforhodamine diffusion and then sectioned for viewing by fluorescence microscopy. 
Within each scleral slice, the sulforhodamine concentration appears uniform, which 
indicates that vertical diffusion occurred at the same rate, independent of position in the 
horizontal direction. This observation is consistent with modeling sulforhodamine 
diffusion as a one-dimensional process. Scleral sections collected further from the 
sulforhodamine donor solution show progressively lower sulforhodamine concentrations 







Figure 4.1.1.  Representative cross-sectional views of human cadaver sclera containing 
sulforhodamine imaged by fluorescence microscopy.  One end of the sclera (A), which 
had been submerged in a sulforhodamine donor solution for 24 h, contains a large 
concentration of the model drug.  Progressively less sulforhodamine is seen in scleral 
sections located further away at distances of (B) 3.25 mm, (C) 6.50 mm and (D) 9.75 mm 




4.1.3. Quantifying lateral diffusion within the sclera 
To quantify the lateral diffusion profile within the sclera, sulforhodamine 
concentration was measured in the scleral sections as a function of both time and distance 
along the sclera.  Figure 3 shows the resulting concentration profiles over a distance of 11 
mm along the sclera at time points between 4 h and 1 week (i.e., 168 h).  After 4 h, 
sulforhodamine diffusion was detected at a distance up to 5 mm along the sclera. After 1 
week, sulforhodamine diffused further than 1 cm along the sclera. At each time point, 
concentration decreased with increasing distance (analysis of variance ANOVA, p < 
0.0001), which is consistent with the pattern seen in Figs. 2 and 3.  Over time, the 
sulforhodamine concentration at each position increased with time (ANOVA, p < 0.0001).   
 
4.1.4. Determining lateral diffusivity 
 To determine the effective lateral scleral diffusivity of sulforhodamine from the 
data in Fig. 3, we employed a theoretical model of one-dimensional diffusion (Eq. 12). 
As parameters for this model, we measured the sclera-to-saline distribution coefficient, 
KD, experimentally to be 13.6, which indicates a strong binding between sulforhodamine 
molecules and the sclera tissue.  The free-to-bound sulforhodamine ratio, Keq, was then 
calculated to be 0.08 using Eq. 8.  This left sulforhodamine diffusivity, Dlat, as the only 
unknown variable. The diffusion model was then fitted to the experimental data, as 
shown in Fig. 4, which yielded an effective sulforhodamine diffusivity of Dlat = 3.82 x 
10-6 cm2/s.  






























0 3 6 9Position (mm)
4 24 48 72 168Time (h)



















Figure 4.1.2.  Lateral diffusion profiles of sulforhodamine in human cadaver sclera as a 
function of time and position. At each time point, the spatial distribution of 
sulforhodamine is shown, where the bar on the left of each set corresponds to sclera 
bathed in the donor solution and each consecutive bar to the right corresponds to 750 µm 
increments in position away from the donor solution.  Average values with standard error 
bars are shown for n = 3 replicates. 
 
 Visually, the predicted curves in Fig. 4.3 capture the trend of the data, but show some 
disagreement.  The quality of this fit can be gauged quantitatively by its mean absolute 
percent error of MAPE = 39%, which indicated that predicted values were on average 
within 39% of experimental values. This uncertainty can be compared to the average 
standard error associated with experimental measurement (i.e., average of error bars in 
Fig. 4.2), which was calculated to be 60%. Thus, the error associated with the 
experimental measurements is greater than the disagreement between the theoretical 
model and the experimental data. This means that the theoretical model predictions are as 































































Figure 4.1.3.  Experimental measurements and theoretical predictions of sulforhodamine 
concentration in human cadaver sclera as a function of time and position.  Experimental 
data points show good agreement with theoretically predicted curves (Eq. 12) using 
experimentally determined values for KD = 13.6 and Keq = 0.08 and a fitted value for 
diffusivity, D = 3.82 x 10-6 cm2/s at 4 h (■), 24 h (□), 48 h (▲), 72 h (∆) and 168 h (♦).  
The experimental data are the same as shown in Fig. 4.1.2.   
 
Further examination shows that at early times (e.g., 4 h), the model generally 
underpredicted the data, whereas at later times, the model generally overpredicted the 
data. This can be explained by a changing diffusivity, which was initially larger than the 
overall fitted value and later was smaller. Diffusivity might have changed over time due 
to changes in tissue hydration. Although the sclera was maintained in a humid 
environment, some tissue de-hydration could have occurred over the course of the 1-
week experiment. Decreasing tissue hydration could progressively decrease diffusivity in 
the sclera as the aqueous diffusion pathways decrease in number and size. In addition, 
decreased water content of the sclera could also decrease average tissue sulforhodamine 
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concentrations by decreasing the aqueous regions containing sulforhodamine relative to 
the collagen, GAG and other insoluble regions.  






















































Figure 4.1.4.  Theoretical prediction curves of sulforhodamine concentration in human 
cadaver sclera with the sclera-to-saline distribution coefficient, KD = 1, as a function of 
time and position at 4 h ( ), 24 h (……...), 48 h ( ), 72 h ( ) and 




As a modification o the model, the sclera-to-saline distribution coefficient, KD, 
was set equal to 1 in Eq. 12 to assess the significance of binding on the prediction model.  
The resulting predicted curves still displayed a similar trend of the diffusion length of 
sulforhodamine along the sclera tissue over each time period; however, the model greatly 
underpredicted the sulforhodamine concentrations within the tissue by a factor of 13.6, 
which was equivalent to KD.  This shows that without KD, the model will still 
qualitatively predict the time dependent of the diffusion profile, but quantitatively it will 
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underpredict the concentrations by an order of magnitude.  This further shows the 
importance of explicitly considering possible binding o drugs to sclera when predicting 
their lateral diffusion. 
 
4.1.5. Comparing lateral and transverse diffusivities 
  To compare lateral and transverse diffusion in the sclera, we measured the rate of 
transverse diffusion of sulforhodamine across the sclera, which provided an effective 
diffusivity of Dtrans = 1.28 ± 0.22 x 10-6 cm2/s, which corresponds to a permeability of 
2.15 ± 0.37 x 10-5 cm/s. These values compare well with previously reported 
experimental data for scleral permeability of other molecules of similar molecular weight 
(Prausnitz and Noonan 1998) and to a predicted diffusivity value of 2.5 x 10-6 cm2/s for 
sulforhodamine generated using an independent theoretical model described previously 
(calculation not shown) (Edwards and Prausnitz 1998). 
  Comparing the lateral (Dlat = 3.82 x 10-6 cm2/s) and transverse (Dtrans = 1.28 x 10-6 
cm2/s) diffusivity values generated in this study indicates that diffusing in the lateral 
direction occurs three times faster than in the transverse direction. Although a rigorous 
analysis of statistical significance is difficult due to the way that lateral diffusivity was 
determined, this three-fold difference may be insignificant due to experimental variability. 
If there is a significant difference, then the larger diffusivity of lateral diffusion might be 
explained by the lateral orientation of collagen fibers in the sclera. Diffusion parallel to 
these fibers might encounter less hindrance than diffusion across the fibers, which might 
be more tortuous. However, the importance of the collagen fibers is not clear, since 
diffusion in the sclera is expected to be governed by the extracellular glycosaminoglycan 
 60
matrix (Edwards and Prausnitz 1998), which is randomly oriented (Fatt and Weissman 
1992) and thus should not favor diffusion in any particular direction. 
 
4.1.6. Discussion 
  This study provides the first measurements of lateral diffusion in the human sclera.  
As new modalities for the treatment of age-related macular degeneration and other retinal 
diseases become available, drug diffusion across and within the sclera to target the 
posterior segment will become increasingly important.  For example, after peribulbar or 
other periocular injection, drug may diffuse across the sclera to reach targets in the 
choroid or retina. Because retinal diseases are often disseminated, it may be desirable for 
drug to diffuse laterally to cover a larger area of retina beyond the site of injection. This 
may be especially important in the case of localized, slow-release drug delivery devices 
placed on the sclera, such as a scleral buckle or other implanted devices 
  Data from this study showed that after just 4 h, measurable concentrations of 
sulforhodamine were present at a distance of 5 mm from the donor solution, but 
measurable concentrations at 10 mm required 3 days. This is consistent with a calculation 
using the value of lateral diffusivity determined in this study: at a distance of 1 cm, the 
characteristic diffusion time is (1 cm)2 x (3.82 x 10-6 cm2/s)-1 = 2.6 x 105 s = 3.0 days. 
Based on a similar calculation, it should take at least 6 weeks for sulforhodamine to 
diffuse from a localized source throughout all of the sclera in a human eye (using a 
characteristic distance of 3.75 cm, which is half the circumference of a human eye (Fatt 
and Weissman 1992). 
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  Although only validated using one compound, the model developed in this study 
for scleral diffusion is general. It should be valid for both hydrophilic and lipophilic 
compounds, as well as small drugs and macromolecules, given knowledge of their 
effective diffusivity, distribution coefficient and binding constant in the sclera, as shown 
in Eq. 12. Effective diffusivity should be strongly reduced by increases in molecular size, 
but only weakly affected by lipophilicity. Binding constant and distribution coefficient 
(which is strongly influenced by the binding constant) should be strongly influenced by 
molecular properties, such as lipophilicity. 
  Measurements and calculations of lateral diffusion in this study have assumed that 
diffusion is one-dimensional and no drug exits the sclera along its choroidal or episcleral 
surfaces. In the in vivo scenario, from a drug implant source within the sclera, some drug 
might be lost due to the “early leakages” of drug into various escaping routes, such as the 
choroid, periocular space and tear film; therefore the lateral distribution of drug within 
the sclera is expected to be even slower.  A further modified model will then be needed to 
address these drug escaping routes.  Moreover, because diffusion in sclera is known to be 
a strong inverse function of molecular size (Prausnitz, Edwards et al. 1998), lateral 
diffusion of proteins and other macromolecules is expected to be one or more orders of 
magnitude slower than sulforhodamine.
  This slow lateral distribution indicates that if delivery localized on the millimeter 
length scale is desirable, then drug administration to a particular site in or on sclera will 
remain highly localized on a timescale of hours to days. Conversely, if lateral distribution 
of drug over a larger area with faster kinetics is required, then a less localized injection or 
implant that covers a larger area of scleral surface may be needed. Moreover, drug 
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distribution by the vasculature in the choroid has not been considered in this analysis and 
may provide a means for additional drug distribution over larger areas. 
 
4.1.7. Conclusion 
 Lateral diffusion of sulforhodamine, a hydrophilic model drug, was studied in 
human cadaver sclera. Measurable amounts of drug were detected at distances of 5 and 
10 mm from the drug donor reservoir at 4 h and 3 days, respectively. Experimental data 
were used to calculate an effective lateral diffusivity of 3.82 x 10-6 cm2/s. This calculation 
enabled the prediction that a point source of sulforhodamine would require 6 weeks to 
diffuse throughout all of the sclera in a human eye. Comparison of experimental 
measurements of lateral diffusion within the sclera to transverse diffusion across the 
sclera indicated similar effective diffusivities, although lateral diffusion was 
approximately three times faster. A theoretical model for one-dimensional diffusion in 
the sclera was developed and shown to match experimental data with a mean absolute 
percent error of 39%. This model can be used to predict rates of lateral diffusion in the 
sclera for various drug delivery scenarios. Altogether, this study shows that lateral 
diffusion in the sclera is a slow process that localizes drug distribution on the millimeter 
length scale for hours to days; lateral diffusion over larger surface areas could occur over 
longer times, for example, during extended release drug delivery from an implant. 
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4.2 Ocular drug delivery using solid coated microneedles 
 
Drug delivery to the eye is notoriously difficult, especially delivery of 
macromolecules and delivery to the back of the eye.  In this study, we propose that 
microneedles can be used as a minimally invasive method to deliver drugs into the eye 
via either intrascleral or intracorneal routes. This work leverages existing technology to 
fabricate microneedles and was guided by existing experience using microneedles for 
drug delivery across the skin. These microneedles can be inexpensively mass-produced 
by adapting the technology of the microelectronics industry.  Given that microneedles 
have not been previously studied for ocular drug delivery, this study sought to design, 
fabricate and test microscopic needles that penetrate just hundreds of microns into ocular 
barrier tissues and deliver drugs into the eye.  
 
4.2.1 Characterization of coated microneedles  
 Single solid microneedles were made by laser-cutting needle structures from 
stainless steel sheets.  Fig. 4.2.1 shows the size comparison of a single stainless steel 
microneedle to a penny.  Guided by the average human sclera thickness of 600 ± 49 µm 
(Lee, Geroski et al. 2004) and possible tissue deformation during the needle insertion, the 
microneedles used in scleral in vitro insertion tests were 750 µm in length, 200 µm at 
needle base and 55o in tip angle.  For in vivo experiments, the microneedles were 
modified to 500 µm in length and 45o in tip angle, to avoid the penetration through the 
thinner cornea tissue.  To handle these microneedles using forceps during the insertion, 
an extended metal substrate attached to the needle base, which normally was 1 cm in 




Figure 4.2.1.  Bright field microscopy image of a single solid stainless steel microneedle 
used in in vivo insertion experiments shown next to a penny.  A close view of the needle, 
which is 500 µm in length and 45o in tip angle, is shown at the upper left corner of the 
figure 
 
Using a formulated coating solution, different drug molecules, sizing from 
fluorescein to DNA, were coated onto the shafts of the microneedles as shown in Fig. 
4.2.2.  After tissue insertion, these hydrophilic coatings were designed to rapidly dissolve 
off the needle.  In addition, using a modified coating apparatus, arrays of multiple 
microneedles were coated with compound solutions.  Development of these methods, 









Figure 4.2.2.  Solid stainless steel microneedle coated with different molecules, such as 
sodium fluorescein (A), fluorescein-labeled bovine albumin (B), and fluorescein-labeled 
plasmid DNA (C) using dip-coating method.  Similarly, arrays of SS microneedles can 
also be coated and used in delivery experiments (D). 
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4.2.2 In vitro microneedle insertion 
After coating the microneedles, we tested their ability to insert into human 
cadaver sclera in vitro.  To qualitatively visualize the insertion site created by the 
insertion, single, clean, microneedles were manually pierced half-way into the sclera 
tissues to avoid full penetration, and immediately after needle removal, blue tissue dye 
was applied on top of the tissue and then wiped off.  The histological image was shown in 
Fig. 4.2.3A.  Using bright field microscopy, the top surface of the sclera was stained by 
the blue dye while the insertion gap created by the microneedle was evident within the 
tissue.  The measured gap distance of 300 µm is similar to the half microneedle length, 
which also indicates only partial needle penetration into the sclera, due in part to tissue 
deformation during insertion.  
Sulforhodamine-coated microneedles were also tested.  After each insertion, the 
microneedles were left within the tissue for 20 sec, allowing the dissolution of the coating 
the needle.  The representative histological image shown in Fig. 4.2.3B indicates that the 
sulforhodamine coating was deposited through the microneedle hole, as well as some 
deposition on the tissue surface. The sulforhodamine fluorescein intensity appears much 
brighter around the needle insertion site compared to the scleral regions away from the 
insertion.  This image shows that the sulforhodamine coating was able to instantly 
dissolve off the needle shaft and diffuse within the tissue.  Similar results were obtained 
from BSA-coated microneedle insertion (Fig. 4.2.3C).   
After each insertion experiment, the microneedles were examined using bright-
filed microscopy for any mechanical defects.  No observations of either needle breakage 
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or bending were reported, which suggested that these microneedles were sufficiently 






Figure 4.2.3.  Histological sections of human cadaver sclera pierced with single solid SS 
microneedles and subsequently stained with a blue tissue marking dye (A), using 
sulforhodamine-coated needles (B) and using FITC-labeled BSA-coated needles (C).  
The arrow in each image indicated the direction of microneedle insertion. 
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4.2.3 In vivo fluorescein delivery 
 We next tested the ability of using coated microneedles to deliver drugs into the 
eye in a rabbit model in vivo.  Using calibrated spectrofluorometry, each solid 
microneedle was coated with 280 ± 14 ng of NaFl.  In initial experiments, we inserted 10 
NaFl-coated needles into the rabbit sclera and attempted to deliver the molecules into the 
vitreous body of the rabbit eye.  However, the amount of fluorescein delivered by 
microneedles was insufficient to be detected in the vitreous body due to dilution in its 
relatively large volume.  To facilitate fluorometric analysis and imaging, we chose to 
deliver fluorescein into the rabbit cornea, rather than the sclera.  After a single NaFl-
coated microneedle insertion, the fluorescein concentration in the anterior segment of the 
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Figure 4.2.4.  Fluorescein concentration profiles in the rabbit eye as a function of position 
in the anterior chamber after NaFl-coated microneedle delivery (A) and topical 
administration of equivalent dose (B). 
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As shown in Fig. 4.2.4, fluorescein concentration was measured over time as a 
function of the distance along the visual axis from the cornea to the lens in the rabbit eye.  
Prior to the microneedle insertion, almost no fluorescein was detected in both the aqueous 
humor and the lens of the eye.  Immediately after the needle insertion, a sharp increase of 
the fluorescein concentration was observed in both regions compared to the background 
fluorescein reading.  The measured concentration reached to the peak after 3 h, and 
gradually decreased to the background level within 24 h.   The fluorescein concentration 
profile in Fig. 4.2.4A suggested that after the fluorescein coating dissolved off the 
microneedles, a depot was formed within the cornea that steadily released fluorescein for 
hours.  For comparison, we performed a control experiment using a conventional topical 
application of equivalent fluorescein dose, and similarly measured the fluorescein 
concentration in the eye over time.  As shown in Fig. 4.2.4B, only small amount of 
fluorescein was detected in the aqueous humor 30 min after topical administration, and 















































Figure 4.2.5.  Average fluorescein concentration in the anterior chamber of the rabbit eye 
delivered by microneedle insertion (gray bars) and topical administration of equivalent 
dose (black bars).  Single coated microneedle delivered more than 60 times higher 
amount of fluorescein over a prolonged time comparing to topical administration. 
 
To compare microneedle delivery and topical application delivery, Fig. 4.2.5 
shows average measured fluorescein concentration in the aqueous humor at each time 
point for each delivery method.  The improved efficiency of microneedle delivery is 
evident, showing that microneedle delivered a significantly larger amount of fluorescein 
into the eye over a longer period. 3 h after application, the dose delivered by a single 
coated microneedle was 60-fold higher than that of topical delivery. 
A useful control experiment would be to make a single, un-coated microneedle 
insertion into the rabbit cornea, topically apply the fluorescein solution on the cornea, and 
then measure the fluorescein concentration in the anterior segment of the eye to examine 
whether microneedle insertion would improve the topical drug delivery efficiency by 
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locally increasing corneal permeability at the site of needle insertion.  Even though this 
experiment has not been done yet, theoretically we can estimate both mass fluxes through 
the cornea and through the hole made by microneedle insertion.  We hypothesize that the 
flux through the microneedle insertion hole will be much less than the flux through the 
cornea. 
The fluorescein flux across the cornea can be estimated as: 
ACPflux **=      (20) 
where A is the surface area of rabbit cornea at 1.6 cm2 (Mietz, Addicks et al. 1994), C is 
the applied drug concentration, which is assumed as 300 ng/ml, and P is the corneal 
permeability to fluorescein that is 5.0x10-6 cm/s (Hale and Maurice 1969).  The mass flux 
across the cornea is then calculated as 2.4x10-3 ng/s.  The mass flux of fluorescein 







≅      (21) 
where Apore is the surface area of microneedle insertion gap of 8.5x10-5 cm2, C is the 
applied drug concentration at 300 ng/ml, D is the diffusivity of fluorescein in water that is 
reported as 6.4x10-6 cm2/s (Galambos and Forster 1998) and depith is the thickness of 
corneal epithelium layer, which is reported as 45 µm (Reiser, Ignacio et al. 2005).  The 
fluorescein mass flux through the hole created by microneedle insertion is then obtained 
as 3.6x10-5 ng/s, which is 150-fold less compared to the flux through the cornea.  This 
finding agrees with our hypothesis and shows that the microneedle insertion by itself has 
an insignificant impact on drug delivery to the eye.  In order to improve drug delivery 
efficiency using topical application, hundreds of single microneedle insertions will be 
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needed, which is not ideally suitable for clinical applications due to safety concerns and 
patient convenience. 
 
4.2.4 Microneedle delivery efficiency 
In order to assess bioavailability of microneedle delivery, we determine the total 
dose of fluorescein delivered into the eye.  Using Eqn. 19 described in the Method 
Section to analyze the experimental data shown in Fig. 4.2.5, the estimated fluorescein 
delivered into the aqueous humor was calculated to be 196 µg, which is equal to 69% of 
the dose of fluorescein coated on the microneedle.  To further investigate the delivery 
efficiency of microneedle, an additional experiment was carried out.  We inserted NaFl-
coated microneedles into rabbit cadaver cornea, and measured the fluorescein content 
within the cornea tissue and that remaining on the needle.  This analysis determined that 
on average 74 ± 27% of the needle coating was delivered into the cornea in vitro, which 
is similar to the result obtained from the in vivo estimation.  Combining the two findings, 
these data also suggested that most fluorescein was released from the needle to form the 
depot in the cornea tissue to provide further release with a bioavailability of 
approximately 70%.  The remaining fluorescein might have been washed away by the 
tear fluid before entering the aqueous humor.  
 
4.2.5 In vivo pilocarpine delivery  
 To further demonstrate the capability of using microneedles to deliver drugs into 
the eye, pilocarpine, a drug known to cause pupil contraction and used in treatment of 
glaucoma, was coated onto 5 single solid microneedles, which were later inserted into 
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rabbit cornea in vivo.  The size of the rabbit pupil was both measured as a function of 
time and imaged at each time point, as shown in Fig. 4.2.6 & Fig. 4.2.7.   Microneedle 
delivery caused a much more rapid and prolonged pupil contraction compared to a topical 
application of equivalent dose.  The pupil size after microneedle insertion was reduced 
from 8 mm down to 5 mm, where topical application only reduced the pupil to 7 mm.  In 
another control experiment, a drop of ophthalmic solution, which containing a 
pilocarpine dose at 10 times greater than that administered by microneedles, was applied 
topically to the eye.  Despite the large drug dose difference, this topical delivery gave 



































Figure 4.2.6.  The measured diameter of rabbit pupil changes over time of negative 
control (  ), topical application of a dose equal to microneedle coating dose 
(  ), pilocarpine-coated microneedles delivery (  ), and topical application of 
1% ophthalmic solution (  ).  Average measurements with the standard errors are 







Figure 4.2.7.  Representative images of rabbit pupil before and 20 min after and topical 
application of pilocarpine solution of a dose equivalent to microneedle coating dose (A 
and B), five pilocarpine-coated microneedles delivery (C and D) and topical application 
of 1% ophthalmic solution (E and F). 
 
 
4.2.6 Safety Exam 
A final experiment was carried out to assess safety of microneedle insertion into 
the eye. Based on three replicate experiments, a single, non-coated microneedle was 
inserted into rabbit cornea in vivo.  As a standardize clinical test, inflammatory response 
in the eye can measured by the degree of cells and flare, using a grading system from 1 to 
4,  in the anterior chamber (Soheilian, Karimian et al. 1997),   These experiments 
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indicated that the insertion wound was no longer visible after 3 h and no cell-and-flare 
response was reported, which suggested there was no inflammatory response. This 
analysis suggests that microneedle insertion into the eye may be well tolerated.  
 
4.2.7 Implications for ocular drug delivery 
Many inflammatory and proliferative diseases in the posterior segment of the eye, 
such as macular degeneration and diabetic retinopathy, require long-term 
pharmacological treatment.  However, it is difficult to deliver effective drug doses to the 
back of the eye using conventional delivery methods such as topical application, which 
has poor efficacy. Systemic administration often causes significant side effects (Geroski 
and Edelhauser 2000). Direct injection into the eye is often effective, but requires 
professional training and safety is a major concern (Maurice 2001).   
Because of their small size, microneedles can be inserted into the tissue with 
minimized physiological damage, which would be an asset in ocular drug delivery.  In 
this study, we demonstrated that microneedles are capable delivering drug particles into 
the eye via the cornea or the sclera in a minimally invasive way.  Coupled with a coating 
formulation, these needles can be coated with a broad range of drug molecule with sizes 
varying from the small (fluorescein) to the large (DNA).  As a convenient and effective 
procedure, this study showed that ocular tissues could be partially penetrated by 
microneedles and followed by the deposition of drug formulations within the tissue to 
provide treatment for hours.  Compared to topical application and intraocular injection, 
microneedle delivery offered a much improved efficiency without causing significant 
tissue damage. 
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With the consideration of combining with additional systems, such as 
biodegradable polymers or hydrogels, the application of microneedles can provide a 
controlled and prolonged drug delivery.  In addition, the patient compliance should also 
be improved, since this microneedle treatment lasts only for seconds and could provide 
longer-term effect.  With further optimization, microneedles may be a broadly applicable 
technology for ocular drug delivery. 
 
4.2.8 Conclusion 
This study demonstrated that coated microneedles can deliver model drugs into 
the human sclera in vitro and the rabbit cornea in vivo. Additional analysis indicated 
sustained delivery from a depot in the cornea for many hours after microneedle delivery 
with increased bioavailability. Slit lamp examination of microneedle-treated eyes showed 
no adverse events. This study shows for the first time that microneedles might be used for 
ocular drug delivery that microneedles may be applicable in treating diseases of the 
posterior segment of the eye. 
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4.3 Microinfusion using hollow microneedles in sclera 
For the first time, hollow microneedles were used to deliver molecules and 
particles into scleral tissues in this study.  To examine various parameters affecting the 
microinfusion into sclera using hollow microneedles, we microinjected flowed 
sulforhodamine solution into human cadaver sclera and measured the delivered 
volumetric dosage as a function of scleral thickness, needle retraction depth and infusion 
pressure.  Additionally, we delivered nano- and micro-particles into the tissue, and 
examined the effect of hyaluronidase and collagenase on particle delivery.  This study 
was motivated by the goal of using hollow microneedles as a novel ocular drug delivery 
tool to deposit drugs within the sclera to provide controlled release in treating diseases in 
the back of the eye.   
 
4.3.1 Characterization of microneedles 
 
The microneedles used in this study were fabricated using a micro-pipette pulling 
technique.  Practically the desired clinical applications of microneedles are envisioned to 
be using multineedle arrays made of metal that are mass-produced by microfabrication 
using tools from the microelectronic industry.  We chose to use glass micropipettes to 
make the needles due to the easy fabrication process. Despite the long shafts these 
needles have, the needle tip geometric dimensions (i.e. tip opening length, diameter, and 
angle) are similar to those of desired microfabricated metal microneedles.  A 
representative glass microneedle used in this study is shown in Fig. 4.3.1, which has a tip 
opening of 100 µm in length and 40 µm in diameter, and an angle of 25o.  The sharp tip 














Figure 4.3.1.  (A) Front and (B) side views of a representative hollow glass microneedle.   
The microneedle shown has a tip opening radius of 20 µm and length of 100 µm with a 
bevel tip angle of 25o.  
 
Single, hollow microneedles were inserted into human cadaver sclera in vitro to a 
controlled depth and then partially retracted.  Sulforhodamine solution was infused into 
the sclera tissue through the hollow shaft of the needle using pressure-driven flow.  Fig. 
4.3.2a shows the top view of the sclera after microinfusion of sulforhodamine solution.  
In a typical experiment, the distribution of the solution appeared in a circular shape, 
which has a diameter measured from millimeters up to one centimeter, depending on 
infusion conditions. When the tissue was viewed from the backside, the distribution of 
sulforhodamine showed similar pattern.  A previous study showed a delicate architecture 
of criss-crossed lamellae that was aligned in the innermost layers of the sclera, but 
moving further towards the surface, larger, less regular bundles became evident (Raspanti, 
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Marchini et al. 1992).  The solution distribution within the sclera was, therefore, 







Figure 4.3.2.  Top view of a representative human cadaver sclera tissue after a single 
hollow microneedle infusion of sulforhodamine solution as shown in (A) and a 
representative histological, fluorescent image of the microneedle insertion site within the 
tissue (B).   A single hollow microneedle with a beveled tip angle of 25o was inserted 720 
µm into the sclera and then retracted 200 µm out.  Sulforhodamine solution was infused 





Fig. 4.3.2b shows a fluorescein image of a 10 µm-thick histological cross-section 
of scleral tissue after infusion.  A single microneedle was inserted 720 µm into the 
middle region of a scleral piece, and retracted 200 µm to infuse sulforhodamine solution 
into the tissue.  The insertion pathway created by the microneedle is evident, measured at 
300 µm deep and the shape of the insertion gap retained that of the needle tip.  There was 
no clear evidence of tissue deformation due to microneedle compression at the scleral 
surface, although this may have occurred during insertion, but recovered after needle 
removal and imagining.  A lack of compression could be explained by the tightly packed 
fiber arrangements in the upper layers of sclera, which the impact force of the needle 
insertion did not distort the fiber arrangement. The surrounding tissues around the needle 
insertion site were stained by infused sulforhodamine solution, and showed a significant 
difference compared to a control tissue without sulforhodamine injection, and the section 
appeared completely black by fluorescence microscopy. 
 
4.3.2 Effect of scleral thickness and retraction depth 
The human sclera thickness varies from 0.3 to 1.0 mm with respect to the position 
along the scleral globe (Fatt and Wissman 1992).  To examine the effect of the thickness 
gradient on microneedle infusion, the sclera was divided into three different regions 
around the scleral globe:  front (near the limbus), middle (at the equator), and back (near 
the optic nerve).  Guided by the previous observations that subsequent needle retraction 
can induce flow into the tissue (Wang, Cornwell et al. 2006), microneedles were inserted 
into each region of the sclera at a controlled depth (720-1080 µm), and then partially 
retracted. Each retraction displacement was 60 µm and lasted 3 minutes.   
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 The results showed that essentially no solution was delivered into the tissue after 
the initial insertion in all experiments as shown in Fig. 4.3.4.  The delivery did not start 
until a certain retraction distance, normally ranging from 200 to 300 µm depending on the 
scleral region, was achieved. Fig. 4.3.3 shows the volume delivery as a function of 












































Figure 4.3.3.  Effect of microneedle retraction on solution volumetric delivery from a 
representative experiment, in which a single, bevel-tipped, glass, hollow microneedle was 
inserted 720 µm into the middle region of a scleral tissue.  Retractions were made at an 
increment of 60 µm, and the delivery did not start after the needle was retracted 180 µm.  
A total of 15 µl of sulforhodamine solution was delivered into the tissue in this 
experiment after retraction of 150 µm and 240 µm. After 300 µm retraction, solution 
leaking was observed on the scleral surface; and thus no further solution was delivered 
into the sclera (*).  
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Since the scleral tissue at the equator is thinner compared to that near the limbus 
and the optic nerve, typically less retraction (209 ± 92 µm) in the middle region was 
needed compared to that in the front region (287 ± 182 µm) and in the back region (262 ± 
145 µm).  The scleral fibers are known to be elastic (Fatt and Wissman 1992), and the 
elastic system appears to be largely confined to the deeper layers in the sclera (Raspanti, 
Marchini et al. 1992), which could explain the zero volumetric delivery at the initial 
phase.  After the needle penetrated into inner layers of the sclera, the fibers were 
deformed due to the compression of needle tip and blocked the needle tip opening.  As 
the needle was retracted back into the upper layer, where the fibers were less elastic, 
larger openings between the needle and collagen fibers were formed and allowed the 

















































Figure 4.3.4.  Effect of microneedle retraction on volumetric delivery into different 
regions of human cadaver sclera, which on average up to 18 µl solution was delivered 
into the tissue at a pressure of 15 psi using a single, glass, hollow microneedle with a 
beveled tip of 25o.  Data are expressed at mean value (n ≥ 17) with standard deviation 
bars. 
 
On average in the middle region, a larger volume of sulforhodamine solution (18 
± 6 µl) was delivered into the tissue comparing to the amount delivered into the front (12 
± 4 µl) and the back (13 ± 5 µl) regions upon needle retraction.  Statistics showed that 
even though a difference was observed among the sulforhodamine dose delivered into 
scleral regions with different thickness, this difference was not significant and  the scleral 





4.3.3 Effect of infusion pressure 
Guided by previous results in a transdermal study (Martanto, Moore et al. 2006), 
we hypothesized that by increasing the infusion pressure we should increase the flow rate, 
which should result in an increase in total volume delivery of the solution.  However, our 
results indicated that pressure had an insignificant effect on the delivery (ANOVA, p = 
0.83) as shown in Fig. 4.3.5, and the flow rates did not change with increased pressure.  
This suggested that the limiting factor in determining the amount of flow with the sclera 
could be the tight-packed collagen fibers.  The elevated pressure was not sufficient 
enough to distort the fiber arrangement to open up the pathways allowing the solution to 































Figure 4.3.5. Effect of pressure on volume of delivery by single hollow glass 
microneedles. Experiments were carried out at pressure of 5 (  ), 10 (  ), 15 (  ), 20 
( ) and 25 (  ) psi.  Single hollow microneedles with a beveled tip angle of 25o were 
inserted 720 µm into each region of the sclera and retracted 140-300 µm out from the 
tissue. Data are expressed as mean values (n ≥ 3) with standard deviation bars. 
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4.3.4 Delivery of nanoparticles 
Fig. 4.3.6 shows a bright-field histological image of a human cadaver scleral 
tissue after infusion of 1.0 wt% nanosphere suspension using a hollow microneedle using 
bright field microscopy.  The insertion depth was measured to be 500 µm, and the 
distribution of the particles is clearly present within the tissue.  Unlike the results from 
sulforhodamine infusion experiments, the nanoparticles did not spread widely within the 
tissue.  Concentrated particle regions were evident around the microneedle insertion gap, 




Figure 4.3.6.  A representative histological image of human cadaver sclera after 1.0 wt% 
nanosphere suspension infusion using a single, beveled-tip, hollow glass microneedle.  
The needle was inserted 720 µm into the front region of sclera, and then retracted 240 µm.  
The nanosphere suspension was infused into the tissue at a pressure of 15 psi.  The top 
arrow indicates the site of the microneedle insertion, and the gap between both arrows 
represents the insertion depth, which is about 500 µm.   
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Fluorescent images showed that the amount of nanoparticles infused into the scleral 
tissue increased as the concentration of particles in the donor solution increased in each 
region of the sclera as shown in Fig. 4.3.7.  Larger fluorescent areas were detected with 































































Figure 4.3.7.  Representative histological fluorescent images of human cadaver sclera 
after infusion of various nanosphere suspensions with single hollow glass microneedles.  
The nanosphere mixtures had solid contents of 0.5, 1, 5 and 10 %.  Microneedles were 
inserted 720-1080 µm respective to the scleral thickness in each region of the sclera, and 
then retracted 240-360 µm.  In each experiment, 20 µl nanosphere suspension was 
infused into the tissue at a pressure of 15 psi.  The dotted lines in each image represent 
the scleral thickness.   
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4.3.5 Delivery of microparticles 
Another goal of this study was to deliver microparticles into the sclera tissue 
using hollow microneedles.  The microparticles had diameters of 1 µm, and we failed to 
deliver any significant number of the larger particles into the tissue in a majority of the 
experiments. The microparticles appeared to clog the tip of the hollow microneedles (data 
not shown).  A control experiment was performed to determine whether the clogging was 
caused by the size of the microspheres relative to the small needle bore size.  We loaded 
single, hollow microneedles with 20 µl microsphere solution each, and infused the 
solution into the air, such that there was no physical tissue barrier induced.  We did not 
experience any needle clogging and therefore concluded that the presence of scleral tissue 
played a critical role in blocking flow.   The collagen fibers in the human sclera are 
reported to vary from 160 to 220 nm in diameters (Raspanti, Marchini et al. 1992), and 
their center-to-center spacing varies between 250 and 280 nm (Edwards and Prausnitz 
1998).  Therefore, we hypothesize that the nanometer-scale spacing between scleral 
collagen fibers might serve as the main barrier during the microparticle delivery, which 
restricted large-sized microspheres to pass.  
Previous analysis (Ethier 1983) also demonstrated the importance of the 
noncollagenous proteins in determining the molecule transport in the sclera.  These 
proteins make up 10% of the scleral dry weight (Fatt and Wissman 1992), and some of 
them are associated with GAGs and together form proteoglycan complexes (the GAGs 
form side chains that are chemically linked to a core protein) ((Edwards and Prausnitz 
1998).  The junctions of these proteoglycan complexes might also play an important role 
in microparticle particle delivery. 
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4.3.6 Effect of hyaluronidase 
  Hyaluronidase is a spreading or diffusing enzyme, which modifies the 
permeability of connective tissue through the hydrolysis of hyaluronic acid, a 
polysaccharide found in the intercellular ground substance of connective tissue.  Previous 
studies have shown the use of it to reduce flow conductivity of dermis during injection 
(Bruera, Neumann et al. 1999; Kreil 1999; McGuire and Yuan 2001).  We therefore 
hypothesized that this enzyme could similarly enhance microsphere delivery into sclera 
by breaking down the GAGs in the scleral extracellular matrixes.  
Using a purified ovine testicular hyaluronidase, Vitrase, which is commercially 
available and is FDA-approved for human use, we carried out two sets of tests as 
described in the Methods Section.  Compared to the histological images of the control 
experiment in which no hyaluronidase was used, a significantly larger dose of 
microspheres was delivered into each region of the scleral tissue that was soaked in the 
hyaluronidase solution prior to the infusion experiment as shown in Fig. 4.3.8.  The same 
effect also took place in the hyaluronidase-mixed infusion tests showing that the effect of 
hyaluronidase is extremely rapid.  This finding supported our hypothesis that by breaking 














Figure 4.3.8.  Representative histological images of the effect of hyaluronidase on 
delivery of 1.3 wt% microsphere suspension using hollow glass microneedles into human 
cadaver sclera.  Two types of experiments were performed:  first, sclera was presoaked in 
a hyaluronidase solution for 1 h prior to microinfusion, and second, the microparticle 
suspension was mixed with hyaluronidase and infused into sclera.  In each experiment, a 
single, beveled-tip, hollow, glass microneedle was inserted 720-960 µm into the sclera 
and then retracted 250-300 µm depending on the scleral thickness in the region.  20 µl of 








Additionally, we also repeated the sulforhodamine solution infusion experiments with the 
addition of hyaluronidase and we did not observe any noticeable change in the volumetric 
delivery.  This suggested that the spacing in the scleral extracellular matrices affects the 
delivery of micron-sized particles, but not small molecules. 
 
4.3.7 Effect of collagenase 
Collagens are defined as molecules contributing to the structure of extracellular 
tissue matrices (Kielty and Grant 2002).  The collagen fibers within the human sclera are 
arranged in a very complex way:  in the innermost layers a delicate architecture of criss-
crossed lamellae is easily seen, but moving further towards the surface larger, less regular 
bundles become evident (Raspanti, Marchini et al. 1992).  This fiber arrangement could 
affect particle delivery within the sclera.  Type I, III, V and VI collagen are presented in 
the sclera, although both biochemical analyses (Keeley, Morin et al. 1984) and light 
microscopy immunolocalization (Tengroth, Rehnberg et al. 1985; Thale, Tillmann et al. 
1996)  have shown that type I predominates.   
Collagenase, an enzyme that breaks down the native collagen that holds animal 
tissues together, was also used in this study to examine its effect on microparticle 
delivery within the sclera.  Similar to the results from the hyaluronidase tests, the 
histological images in Fig. 4.3.9 showed that either pre-soaking the tissue in collagenase 
solution or adding collagenase to the microparticle suspension increased the amount of 
microspheres infusing into the scleral tissue.  This finding also agreed with our 
hypothesis that the tight architecture of the collagen fibers served as a critical barrier in 











Figure 4.3.9.  Representative histological images of the effect of collagenase on the 
delivery of 1.3 wt% microsphere suspension using hollow glass microneedles into human 
cadaver sclera.  Two types of experiments were performed:  first, sclera was presoaked in 
a collagenase solution for 1 h prior to microinfusion, and second, microparticle 
suspension was mixed with collagenase and infused into sclera.  In each experiment, 
single, beveled-tip, hollow glass microneedle was inserted 720-960 µm into the sclera 
and then retracted 250-300 µm depending on the scleral thickness in the region.  A 20 µl 










4.3.8 Implications for ocular drug delivery applications 
 This study shows that hollow microneedles can infuse fluid solutions containing 
particles varying from small-sized molecules (about 500-600 Da) to micron-sized 
particles (about 1 µm in diameter) into sclera after partial needle retraction within the 
tissue.  Unlike previous results showing in transdermal delivery, the volumetric delivery 
was independent to the infusing pressure possibly due to the complex alignment of the 
scleral collagen fibers.  Microspheres were only delivered into the sclera with the 
presence of either hyaluronidase or collagenase.   These effects can be explained by the 
overall hypothesis that microinfusion through hollow microneedles into sclera is limited 
by the resistance to flow offered by the naturally tightly packed collagen fibers.  Needle 
retraction may induce flow by creating open pathways between the needle and the fibers.  
Both hyaluronidase and collagenase attack extracellular matrix structures within the 
sclera to break down collagen and GAG fibers to allow microspheres to flow through.   
 This study is significant because for the first time, hollow microneedles have been 
used to deliver solution and particles into the ocular tissue in a controlled fashion.  In 
contrast to hypodermic injection, the microneedle system can deposit drug particles 
within the sclera with minimized tissue damage.  The mechanistic interpretation that fiber 
alignment serves as the rate-limiting barrier in scleral delivery provides a rational 
guideline to design new approaches for in vivo applications.  
 Single microneedles were shown to infuse on average up to 30 µl of fluid into 
sclera, which is sufficient for many short-term applications.  In order to provide a 
therapeutic delivery dose, an array containing multiple microneedles is envisioned.  In 
this way combining with drug-encapsulated microspheres, up to hundreds of microliters 
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solution can be delivered into the eye and provide a sustained drug delivery depending on 
the biodegradation of the particles.  Microneedles could be coupled with a user-friendly 
device, such as a commercially available infusion pump, in a potential scenario of clinical 
application.  Aside from drug delivery, we hypothesize that hollow microneedles may 
also be used for fluid extraction; such as removing fluid from the vitreous body of the eye 
to lower intraocular pressure.  Future studies will be needed to assess this possibility. 
 There are limitations to infusion using microneedles.  Typically glass is not the 
ideal material for microneedles for in vivo applications, since breakage of the needle will 
cause additional complications.  Alternative materials, such as stainless steel or 
biodegradable polymers, can be investigated to replace single, hand-drawn, glass needles.  
In addition, the minutes-long duration of the microneedle application suggests that this 
system is not suitable for scenarios required rapid drug delivery.  Finally, the current 
microneedle is designed for laboratory use only; therefore, further modifications and 




 In this study, we demonstrated the ability of using hollow microneedles to deliver 
fluid into the human cadaver sclera, guided by the hypothesis that the infusion is mainly 
limited by the tight alignment of the collagen or GAG fibers.  In a typical experiment, a 
single microneedle can deliver up to 20 µl of solution into the tissue upon needle 
retraction.  Infusion pressure has an insignificant effect on delivery.  By adding either 
hyaluronidase or collagenase, we also delivered micron-sized particles into the sclera.  
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Altogether, this study shows that hollow microneedles can be used as a novel approach to 
deliver drug particles or solutions into the eye in a minimally invasive manner contrasted 
to hypodermic injections.   
  
4.4 Therapeutic drug application using microneedles 
 In this study, we have demonstrated the capability of using either solid 
microneedles or hollow microneedles to deliver molecules into the sclera.  Our next goal 
is to assess this microneedle system for possible delivery of therapeutic agents such as 
Macugen, pilocarpine and methotrexate to treat diseases in the anterior and posterior 
segments of the eye via the sclera. 
 Topical application remains the most common method to deliver drugs into the 
eye.  Pilocarpine (e.g. Timolol) is used to lower the intraocular pressure to treat glaucoma 
(Asseff, Weisman et al. 1973).  Typically a drop of 0.25% Timolol eye drop solution is 
applied twice per day, which suggests that approximately 250 µg drug is delivered onto 
the cornea of the eye on a daily basis (DrugBank).  Previous study (Asseff, Weisman et al. 
1973) reported that only 1-3% or less of an instilled pilocarpine dose gains access to the 
internal eye structures.  Assuming 2% drug bioavailability, only 5 µg drug will reach to 
the back of eye.   Base on this calculation, a total of 150 µg drug is needed for a 30-days 
treatment.  In our study, a single solid microneedle can be coated with up to 3 µg of drug, 
which suggests that 50 microneedles will be needed to meet the dose requirement for 30 
days.  On average, a single hollow microneedle delivered up to 30 µl drug solution into 
the sclera tissue.  Using a solution of pilocarpine at it solubility limit (2.74 mg/ml), 2 
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hollow microneedles are needed to provide the therapeutic dose requirement by infusion 
of 30 µl of solution each. 
 A similar calculation has been done for methotrexate, an anti-inflammatory agent 
to treat uveitis in the eye (Bom, Zamiri et al. 2001).  A topical drop of 0.1% methotrexate 
solution normally is needed for application twice per day, which suggests that only 1 µg 
drug will enter the eye (DrugBank).  Using the same bioavailability assumption of 2%, 
for a 30-day therapeutic treatment, 60 µg methotrexate is needed. This means 20 solid 
microneedles are required while only a single hollow microneedle injection of 30 µl 
solution of methotrexate at its solubility limit (2.6 mg/ml) is needed. 
Ideally a controlled drug release is favored in the eye, and to achieve this goal, 
our microneedle system can be coupled with biodegradable polymer systems, such as 
microspheres and nanospheres.  Assuming a 10% drug encapsulation efficiency in the 
microsphere, 500 solid microneedles will be needed for Timolol delivery and 200 needles 
will be needed for methotrexate treatment.  In the hollow microneedle needle delivery, 
using a donor solution containing 1 wt% of drug-encapsulated microparticles with the 
same encapsulation efficiency, 5 hollow microneedle injections each loaded with 30 µl 
solution are needed for pilocarpine delivery and the number of hollow microneedle 
needed for methotrexate  injection is 2.   
Macugen (Pegatanib sodium injection) is a therapeutic agent used to treat macular 
degeneration in the eye (Pfizer).  Typically, a dose of 300 µg must be injected 
intravitreally every 6 weeks.  On a 30-day period, 210 µg drug is needed.  Based on this 
information, a need of 70 solid microneedles or 2 hollow microneedles, each loaded with 
30 µl of 0.3% Macugen solution, is suggested.  Coupled with the microparticle system of 
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10% encapsulation efficiency, 700 solid microneedles or 7 hollow microneedles, each 
loaded with 30 µl of microparticle solution, will be needed for drug administration. 
 
Drug 30 days 
 
Table 4.1.  The number of microneedles (solid and hollow) required for a 30-day period 
of therapeutic drug (Timolol, Methotrexate and Macugen) administration.  
* indicates topical administration of Timolol (0.25%) and Methotrexate (0.1%) with a 
bioavailability assumption of 2 percent 
** indicates intraocular injection of Macugen 
MN = microneedle and MS = microsphere with a drug encapsulation efficiency of 10% 
 
 
 Based on these estimates, the hollow microneedle system seems to be more 
suitable to treat ocular diseases that need a large amount of therapeutic drug, where solid 
microneedles can be used in the cases that only require modest drug dose (e.g. single-day 









































 Current treatment of ocular disorders in the back of the eye is constrained by 
inadequate drug delivery methods, since topical application can only deliver small 
molecules into the eye and intraocular injections lead to safety concerns.  In this study, 
microneedles were tested to provide targeted drug delivery into the eye guided by their 
previous success in transdermal drug delivery. 
 To better interpret subsequent microneedle studies, we first quantified lateral drug 
diffusion profile within the sclera, by carrying out a diffusion study of a model compound, 
sulforhodamine, through human cadaver sclera, and developing a theoretical model for 
prediction of drug delivery kinetics and distribution.  Experimental results showed that 
the lateral diffusion of sulforhodamine depended significantly on both time and distance 
along the sclera.  After 4 h, sulforhodamine was observed 4 mm along sclera and to 
diffuse as far as 1 cm after 1 week.  Equilibrium experiments further showed a sclera-to-
saline partition coefficient of 13.6, indicating a significant binding between 
sulforhodamine particles and scleral tissue.  Coupling with the theoretical prediction, an 
effective diffusion coefficient was found to be 3.82e-6 cm2/s. Comparison with trans-
scleral diffusion indicated similar diffusion coefficients, although lateral diffusion was 
approximately 3 times faster.  Based on an average human scleral surface area of 16.7 
cm2, these data suggest that it would require up to 7 weeks for sulforhodamine or 
molecules with similar sizes to diffuse from a localized source throughout the scleral 
globe, which is useful to estimate the drug distribution over time from an implantation 
delivery device.  This study presented the first experimental measurements of lateral 
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diffusion within the sclera, and showed this diffusion is a slow process that localizes drug 
distribution on the millimeter scale for hours to days.   
 To examine if microneedles can insert into sclera and deliver drug particles, solid 
metal microneedles of 500-750 µm in length coated with different molecules (small drugs, 
proteins and DNA) were manually pieced into human cadaver sclera.  The tests showed 
that these microneedles were sufficiently strong and sharp to penetrate into the sclera 
without bending or breaking, and were able to rapidly deposit water-soluble drug 
coatings within the tissue after insertion.  Guided by these in vitro results, we assessed 
the system to deliver drugs into an animal model in vivo.  To facilitate imaging and 
fluorometric analysis, fluorescein was delivered to the rabbit cornea.  The measured 
fluorescein concentration profile in the anterior segment of the rabbit eye suggested that a 
drug depot was formed within the cornea and steadily released fluorescein molecules for 
hours.  Microneedle delivery exhibited elevated fluorescein levels in the aqueous humor 
60 times greater than that delivered by topical application of the equivalent dose.  
Similarly, microneedle delivery of pilocarpine caused rapid and extensive pupil 
constriction. We also investigated the efficiency of microneedle –based delivery and the 
analysis indicated that more than 70% of coated fluorescein was released from the needle, 
but a large fraction did not reach the aqueous humor and possibly was washed away by 
the tear fluid, which suggested that further optimization of the system must be needed.  
Additionally, slip lamp exams showed that the insertion site created by the microneedle 
was no longer visible after 3 h and no inflammation or cell-and-flare responses were 
reported.  This study showed for the first time that microneedle can be used to deliver 
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small drugs and macromolecules into the eye in a minimally invasive manner for 
potential treatments of anterior segment diseases, as well as posterior segment diseases. 
 Since hollow microneedles offer extended delivery capabilities, we inserted 
bevel-tipped, hollow glass microneedles into human cadaver sclera for infusion test.  
Despite the thickness variance around the scleral globe, on average 18 µl of 
sulforhodamine solution and a solution containing nanoparticles was delivered into the 
sclera upon retraction of the microneedle.  Due to the densely aligned scleral collagen 
fibers, varying infusion pressure did not have a significant impact on the volumetric 
delivery.  Elevated pressure was not sufficient to distort the fiber arrangements to open 
pathways for solutions to pass through.  Successful delivery of micron-sized particles into 
the sclera could be improved by breaking down tightly packed collagen fibers in the 
sclera.  With the presence of either hyaluronidase or collagenase, we were able to achieve 
microsphere delivery using hollow microneedles.  After encapsulating drugs into the 
microparticles, the delivery can be managed in a controlled fashion.  Altogether, this 
study demonstrated the promise of using hollow microneedles to microinfuse 
therapeutically useful amount of drug solutions into the ocular tissue for various clinical 
applications.   
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6 RECOMMENDATIONS 
This study presented the first results of using microneedles to deliver drugs into 
the eye either through cornea or sclera.  While building off these results, further 
investigations are recommended to optimize this novel ocular drug delivery system, 
especially for the scenarios of in vivo studies.  Both diffusion-based solid microneedles 
and injection-based hollow microneedles showed the promise of providing targeted and 
controlled drug delivery, especially when coupling with biodegradable polymer systems.  
The ultimate goal of the study is to efficiently deliver therapeutic drug doses using single 
or multiple microneedles into the posterior segment of the eye through sclera and 
conjunctiva to treat diseases such as diabetic retinopathy, retinitis, pigmentosa, and 
macular degeneration.   
 Single coated microneedle insertion demonstrated its capability of delivering 
various sized molecules into the human cadaver sclera in vitro, and drugs into the front of 
the rabbit eye in vivo.  However, in order to deliver a large amount of drugs, typically 
ranging from tens to hundreds of micrograms for therapeutic treatment on a weekly basis, 
multi-arrays of microneedles are recommended. Due to the curving scleral surface, 
further optimization of the needle array, such as the geometric design and numbers of 
needles, will be needed.   One possibility is to have variable microneedle lengths in the 
needle array such that needles at the ends are preferably longer than these in the center, 
which corresponds to the scleral curvature.   
In order to provide controlled drug release, coating solid microneedles with 
biodegradable, drug-encapsulated, polymer microspheres is suggested.  After maximizing 
both drug encapsulation efficiency and particle loading efficiency onto the needle shaft, a 
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short-term in vitro insertion test should be carried out to examine the insertion effects, 
followed by in vivo applications in living animals.  Aside from scleral insertion, 
conjunctiva can also used be used as a route for drug delivery to the posterior part of the 
eye.   
Hollow microneedles can deliver larger drug capacities into the sclera compared 
to solid microneedles; however, the current insertion setup is not ideally suited for use in 
the in vivo delivery experiments.  Needed modifications of the apparatus include:  
shortening the length of the infusion tubing, redesigning the microneedle holder targeting 
in vivo delivery scenarios, and using a constant flow rate source (i.e. syringe pump) 
instead the pressure source.  The use of microneedles is envisioned to be in an 
arrangement of multiple needles; thus, a device containing multi hollow microneedles 
should be considered, extending and augmenting the results of single glass needle 
infusion.  In clinical applications, glass is not the ideal material for tissue insertions; 
therefore, alternative material for hollow microneedles, such as stainless steel or 
biodegradable polymers, needs to be looked into.  Ultimately, a compact and user 
friendly hollow microneedle-based device should be built to deliver sufficient drug 
dosage into the eye.  Besides using hollow microneedle as a delivery tool, it can also be 
used in other applications, such as extracting fluids in the vitreous body to lower the 
intraocular pressure.   
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Appendix A.  










MEMS device for controlled drug delivery 
B.1 Introduction 
It is desirable to control the release of drug compounds from within an 
implantable device to the external environment.  The method by which a drug is released 
can have a significant impact on the drug’s therapeutic effect (Bakken and Heruth 1991).   
Conventional drug delivery typically produce a sharp initial increase in drug 
concentration to a peak above the therapeutic range, followed by a rapid decrease in 
concentration to a level below the therapeutic range (Huang and Brazel 2001).  However, 
this initial concentration burst can induce a serious risk of toxicity, and the total time, 
which the released drug spent in the desired therapeutic range, is also short.  Therefore, a 
constant release of drug over long periods is often desirable.  In recent years, a new focus 
in the area of controlled release is pulsatile drug delivery.  For example, insulin 
(Matthews, Lang et al. 1983) and hormones of the anterior pituitary gland such as growth 
hormone and gonadotropin-releasing hormone (GnRH) are secreted by the human body 
in a pulsatile fashion (Santini, Richards et al. 2000).  Various polymer systems have been 
developed for pulsatile controlled drug release that can respond to ultrasound (Kost, 
Leong et al. 1989), changes in pH (Kim, Kim et al. 1992; Lowman, Morishita et al. 1999) 
or temperature (Hoffman, Afrassiabi et al. 1986), electric (Kwon, Bae et al. 1991) and 
magnetic field (Edelman, Kost et al. 1985). 
In this study, we designed, developed and tested a Micro-Electro-Mechanical 
Systems (MEMS) device made out of biodegradable polymers, which is suitable for 
implantation to provide controlled and possible pulsatile drug delivery from weeks up to 
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months.  This device consists of two different parts:  a lower mold containing drug 
reservoirs and an upper covering polymer film of variable thickness.  The device is 
designed to release drugs at different times depending on the degradation rate of the 
covering film, which depends on the film local thickness along its thickness gradient.  
Ideally, as the film degrades, drugs release from the thinnest end to the thickest end.   
 
B.2 Material and methods 
B.2.1 Fabrication of the master structure and the device 
By adapting the fabrication process of the microelectronic industry (Park, Allen et 
al. 2006), a device for controlled drug delivery was made.  A master structure of the 
device was first created using lithography-based methods, followed by the creation of an 
inverse mold using the master structure, and the final device was obtained by melting 




















Figure B1.  The fabrication steps for a MEMS device that provides controlled drug 
delivery.  (a) A SU-8 master structure fabrication using inclined UV lithography, (b) an 
inverted PDMS mold made from the master structure, (c) a PLA mold with built-in 
reservoirs, (d) a PLA mold encapsulated with molecules, and (e) the final MEMS device 
made of a PLA base mold covered with a PLGA film that has a thickness gradient.  
 
 
The master structure was fabricated out of SU-8 epoxy using inclined UV-
lithographic techniques (Choi, Rajaraman et al. 2006) to form negative concave shaped 
structures.  Each structure was a cylindrical well of 125 µm in radius and 600 µm in 
length.  The center-to-center distance between two wells was 640 µm.  SU-8 epoxy (SU-
8 100; MicroChem, Newton, MA, USA) was coated onto a silicon substrate and 
lithographically patterned into desired cylindrical holes to make the master mold.  While 
varying both the mask dimension and the incident angle of UV light, the depth of the 
mold can be controlled. 
 111
After obtaining the master structure, poly (dimethylsiloxane) (PDMS; Sylgard 
184, Dow Corning, Midland, MI, USA) was poured into the mold, applied with vacuum 
at 100 kPa for 1 h to remove the gas bubbles in the solution, and placed inside an 
incubator at 37 oC overnight.  The solidified PDMS was then peeled off to make an 
inverse mold.   
Since PLA is a FDA-approved polymer that is biocompatible with the human 
tissue and has a relatively slow degradation rate (Miller, Brady et al. 1977), it was chosen 
as the material for our base mold.  Solid, poly-L-lactide (L-PLA, 1.0 dl/g; Birmingham 
Polymer) pellets were placed on top of the inverse mold and placed in an oven at 190 oC.  
After all the pellets were melted, vacuum suction was applied at 100 kPa for 5 minutes 
every half hour to remove the air bubbles trapped beneath.  This vacuuming procedure 
normally lasted for 2-3 hours.  The final PLA structure was taken out of the oven, 
compressed against a silicon wafer resting on the table to maintain a flat backside, 
allowed to cool down and finally was peeled off from the inverse PDMS mold.   
 
B.2.2 Encapsulation of molecules in mold reservoirs 
In this study, sulforhodamine (558 Da; Invitrogen, Eugene, OR, USA) and 
polyethylene glycol (PEG, 1500 Da, Acros Organics, New Jersey, USA; a hydrophilic 
and biocompatible polymer) were used to fill the reserviors.  50 mg Sulforhodamine 
powder were dissolved in 1 ml DI water, and solid PEG pellets (500 mg) were then added 
to the solution.  The mixture was stirred at 300 rpm at 40 oC on a magnetic hot plate for 1 
h to remove all the water molecules, which resulting in a solidified PEG cake mixed with 
sulforhodamine.  This PEG cake was re-melted at 50 oC , and 200 µl of the melted 
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solution was pipetted on top of the reservoirs of the PLA mold inside a vacuum oven, 
applied with vacuum suction for 30 min to encapsulate the compounds within the 
reservoirs.  Any residue solution left on the surface of the mold was gently removed 
using a cotton tip.  Because of the presence of PEG, the filling solution was solidified in 
each reservoir at room temperature.   
 
B.2.3 Fabrication of covering polymer film 
An aluminum mold with a surface thickness gradient (slope = 0.013) was made 
by the machine shop in the School of Chemical and Biomolecular Engineering at Georgia 
Tech.  Compared to PLA, the degradation of poly (lactide-co-glycolide) acid (PLGA), 
which is also a FDA-approved polymer, occurs at a faster rate (Witschi and Doelker 1998; 
Lu, Peter et al. 2000).  PLGA is chosen as the material for the covering film.  Solid 
PLGA (50:50; Sigma-Aldrich Inc., St. Louis, MO) pellets were placed in between two 
Nylon films (BASF) on top of the aluminum mold.  A Nylon slab (0.25 in. thick; 
McMaster, Atlanta, GA, USA) was placed above the top Nylon film, while clamps were 
used to tighten the contact between the films and the slab with the structure.  The entire 
apparatus was placed in an oven at 100 oC to melt the PLGA pellets.  After an hour of 
heating, the apparatus was taken out and allowed to cool down to the room temperature 
overnight.  The resulting PLGA film with a thickness gradient at the surface, typically 





B.2.4 Binding of the PLA mold and the PLGA film 
Using a solvent binding method (Vinter 1996), the PLGA covering film was 
attached onto the PLA mold.  The PLA mold and a vial containing 10 ml of chloroform 
were placed inside a vacuum oven at 40 oC, and followed by 30 min of vacuuming.  The 
PLGA film was then placed on top of the PLA mold inside oven.  After another 30 min 
of vacuuming, the film was manually pressed onto the mold using a paint brush to 
complete the binding between the film and the mold.    
We tested two other methods to enhance the binding between the film and mold:  
addition of an extract sealing layer and ultrasonic welding.  For the first methd, solid 
PLA pellets were mixed with methylene chloride (J.T. Baker, Phillipsburg, NJ, USA) at 
an m/v ratio of 50:50.  Using cotton swabs, this mixture was carefully applied onto the 
four edges of the film, as an additional sealing layer at the interface.  An ultrasonic 
machine (VC 505; Sonic & Materials, Inc., Newton, CT, USA) was also used as an 
alternate method to enhance the film binding.  The MEMS device was placed on a flat 
surface, while the ultrasound probe was in contact with the covering film.  The ultrasound 
was applied at a frequency of 20 kHz for 1 s. 
 
B.2.5 In vitro release test 
The sulforhodamine-encapsulated MEMS device was submerged into a 20 ml 
phosphate buffered saline solution (PBS) bath and placed inside an incubator maintained 
at 37 oC and 100% humidity.  At each desired experimental period (1 h, 2 h, 4 h, 1, 2, 3, 7, 
10, 14, 17, 21 and 24 days), a 2 ml sample was withdrawn from the bath and pipetted into 
a cuvette while 2 ml of PBS solution was added back into the bath.  The sulforhodamine 
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concentration inside the cuvettte was measured by calibrated spectrofluorometry (Photon 
Technology International, Lawrenceville, NJ, U.S.A.) at an excitation wavelength of 565 
nm and emission spectra collected at 580 to 620 nm.  The amount of sulforhodamine 
presented in the sample was calculated using the following equation: 
sulfcuvettecuvettecuvette MWVCm **=     (1) 
where Ccuvette  is the measured molar concentration in the cuvette, V is the sample volume 
in the cuvette and MWsulf is the molecular weight of sulforhodamine.  Assuming the 
measured concentration is equal to the concentration in the bath, the total dose of 
sulforhodamine presenting in the donor bath at each experimental time was then 
calculated as: 





where n is the total number of days, i is the sample number and the summation term 
accounts for the total amount of sulforhodamine samples withdrew from the bath.  In 
addition, at each experimental period, a corresponding bright-field (Leica DC 300) image 
of each device was captured, which provided the visual indication for the particle 
releasing pattern within the mold.   
 
B.2.6 Drug encapsulation efficiency  
 Using a filling solution of 100 mg/ml, 3 µg of drug can be encapsulated in each 
reservoir in the device based on its volume; therefore, a single MEMS device of 100 
reservoirs can contain 300 µg drug.  The actual total amount of drug encapsulated in the 
device can be estimated using Eqn. 2 when the maximum sample concentration is 
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ED =     (3) 
where mexperimental is the total amount of drug determined by experimental measurements, 
and mtheoretical  is the theoretical estimation of total amount of drug encapsulated in the 
device.    
 
B.3 Results and discussions 
B.3.1 Fabrication of master structure 
The first step to make our MEMS device for controlled- drug delivery involved 
fabricating a master structure using microelectromechanical systems (MEMS) techniques.  
This master structure was then used to make inverse molds, which were used to make 
replicate polymer base molds for the device.  The basic layout of the master structure is a 
2 x 2 cm square, with a 10 x10 array of reservoirs built-in at its center.  Each reservoir is 
in cylindrical shape that has a radius of 125 µm and a depth of 600 µm, and is able to 
hold up to a few micrograms of drugs.  The center-to-center spacing between the 
reservoirs is 640 µm.  The entire array occupies an area of 6 x 6 mm.  The final PLA 
mold had the same geometric parameters as the master structure.    
 
 B.3.2 Effect of covering PLGA film 
In order to establish a controlled drug release, a thin layer of PLGA film of 
variable thickness was placed on top of the PLA mold.  The particle release was intended 
to be continuously changing guided by the degradation of the PLGA film, where the 
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earliest release came from the reservoirs covered by the thinnest end of the film and 
gradually proceeding to the thickest end.   On average the film thickness gradient was 
measured at 80 ± 12 µm. The thickness at the thinnest end was 20 ± 8 µm and at the 
thickest end was 100 ± 10 µm.   
As a positive control, a PLA mold encapsulated with sulforhodamine without a 
covering PLGA film was placed into a PBS bath.  Immediately afterwards, the drug 
diffused out from the reservoirs and one hour later, all the reservoirs were depleted as 
shown in Fig. B2B.  By comparison, after 1 week, there was still a significant amount of 
sulforhodamine present in the reservoirs of a device that was covered by a PLGA film as 






Figure B2.  (A) A MEMS device without a covering polymer film serves as the positive 
control.  (B) 1 h after the control device was placed into the release bath, all the 
reservoirs were depleted.  (C) A MEMS device covered with a PLGA film varying in 
thickness, from the thinnest end on the right of the mold to the thickest end on the left (D) 
1 week into the release test, most of the sulforhodamine was still remaining in the 
reservoirs. 
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B.3.3 Initial release test results 
In the first trial, sulforhodamine was mixed with melted PEG solution and filled 
into the reservoirs of three PLA molds.  The covering films were then manually pressed 
onto the molds; however, after the film binding, sulforhodamine leakage from several 
reservoirs in the molds was observed.  This could have been caused by the elevated 
temperature inside the vacuum oven, where the binding process took place.  Since the 
oven temperature operated near the melting point of PEG, the filling compounds inside 
the reservoirs were melted again. Due to the manual compression of the PLGA film, 
some liquefied filling solutions were forced out of the reservoirs.  
The release test was carried out over a 30 day period, and the results showed that 
a maximum sulforhodamine concentration measured in the PBS bath was reached after 3 
weeks in each case (Fig. B3).  The normalized sulforhodamine release profile indicated 
an initial sharp boost in the concentration, followed by a gradual concentration increase 
and eventually a leveling concentration.  The initial sharp concentration could be 
explained by the non-uniformity of the film binding using the manual-pressing method.  
At the interfaces between the film and the mold, there were small opening gaps that 
allowed water to enter beneath the film.  The bright field images also agreed with our 
hypothesis, and indicated the early release of sulforhodamine from the reservoirs covered 

























































Figure B3.  Normalized sulforhodamine percentage release profile of the MEMS devices 
(n=3).  Each data point was normalized with respect to the maximum sulforhodamine 
concentration measured in the release bath, which was determined at Day 21, in each 
mold. 
 
A drug encapsulation efficiency of 20% was reported.  This relatively low 
efficiency was caused by the heterogeneous mixture of the filling solution.  After solid 
PEG pellets were melted, it was difficult to dissolve all the sulforhodamine particles in 
the highly viscous PEG solution.  To improve the encapsulation efficiency, in the later 
studies we dissolved sulforhodamine in water first, mixed with PEG and evaporated all 
the water molecules to make a homogenous mixture.  Using this approach, the 
encapsulation efficiency was improved to 33.4±10.3%.   
 
B.3.4 Effects of various film binding enhancements 
The initial release test indicated an imperfect binding between the covering PLGA 
film and the PLA base structure, which caused early leakage of drug from the reservoirs 
 119
covered by the thicker parts of the film.  To fix this problem, two other binding 
enhancement methods, ultrasonic welding and addition of a polymer sealing layer, were 
used after the film was manually bound.  The normalized percentage releasing profiles 
obtained over time are shown as in Fig. B4, where two molds using enhancement 




































Figure B4.  Normalized sulforhodamine percentage release profiles of three MEMS 
devices, each using a different film binding method.  Using the manual pressing method 
only ( ), all the sulforhodamine depleted from the reservoirs after one week.  Both 
enhancement methods using an additional PLA sealing layer (  ) and ultrasonic 
welding ( ) extended the drug release periods to 3 weeks.   
 
The mold that only used manual-press binding method showed a relatively shorter 
release period of 7 days compared to the others.  The images in Fig. B5 show that water 
went underneath the binding film 30 min into the release test. At Day 3, a large cluster of 
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sulforhodamine was evident at the lower left corner in the mold, where the covering film 
was thickest.  A week later most of the drugs had diffused out of the reservoirs.   
 
 
Figure B5.  Images of a MEMS device covered with a PLGA layer using hand pressed 
method at the experimental release periods of (A) 0, (B) 30 min, (C) 1, (D) 3, (E) 8  and 
(F) 13 days.  The leakages of sulforhodamine at the thicker region of the covering film 
were evident, which indicated an imperfect film binding. 
 
Ultrasonic welding is an industrial technique whereby high-frequency ultrasonic 
acoustic vibrations are used to weld objects, such as plastics and polymers, together.   
This method was used to enhance the interface binding between the reservoirs and the 
polymer film, which caused local melting of the polymers due to absorption of vibration 
energy.  By comparison, the mold using ultrasonic enhancement had a longer release 
period of 3 weeks with a gradual increase in the concentration profile.  Even though some 
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reservoir leaks were still detected, it was not as significant as the case using manual-
pressing method only.   
 
 
Figure B6.  Images of a MEMS device covered with a PLGA layer using ultrasonic 
binding enhancement method at the experimental release periods of (A) 30 min, (B) 1, (C) 
3, (D) 7, (E) 11, (F) 14, (G) 21 and (H) 24 d.  Less sulforhodamine leakage was evident 
and after 3 weeks, most of the sulforhodamine was depleted from the reservoirs.   
 
An additional set of experiments was performed using three MEMS devices 
fabricated using the same binding enhancement method, and release data are shown in 
Fig. B7.  Unfortunately, in 2 of 3 molds we experienced early sulforhodamine leakage, 
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which shortened the total release time as a result.  We hypothesize that this leakage could 
be caused by microfractures on the surface of the film created during ultrasonic welding.  
One solution is to reduce the contact time between the ultrasound probe and the film 
while using a lower intensity in the future experiments.  A bigger-sized ultrasound probe 
is also recommended, so that the entire surface of the film will be covered during the 


































Figure B7. Normalized sulforhodamine percentage release profiles of three MEMS 
devices fabricated using ultrasonic binding enhancement.  Mold 1 ( ) showed a 
release period of 3 weeks.  Both mold 2 (  ) and mold 3 ( ) experienced the 
reservoir leakages, which shortened the release period to 2 weeks.   
 
A second binding enhancement was also tested, which was adding a PLA layer at 
the edges of the film to prevent water entering at the interfaces.  A similar release profile 
was obtained compared to that of using ultrasonic welding.  The images showed fewer 
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leaks occurred during the study, and the release profile also showed a steady increase in 
the sulforhodamine concentration over time. 
 
 
Figure B8.  Images of a MEMS device covered with a PLGA layer using a PLA sealing 
layer at the experimental release periods of (A) 30 min, (B) 1, (C) 3, (D) 7, (E) 11, (F) 14, 
(G) 21 and (H) 24 d.  After 3 weeks, most of the sulforhodamine was depleted from the 
reservoirs.   
 
 
B.3.5 Encapsulation of multiple compounds in the device 
 
We attempted to encapsulate two different molecules, sulforhodamine and 
fluorescein (376 Da, Sigma, St. Louis, MO, USA), into the device.  While half of the 
reservoirs were covered with masking tape, the other half was filled with sulforhodamine 
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using vacuum suction.  The same filling technique was then repeated to encapsulate 
fluorescein particles into the other half of the reservoirs.  The PLGA film was attached to 
the mold afterwards for completion.   A resulting MEMS device is shown in Fig. B9.     
 
 
Figure B9.  A MEMS device encapsulated with two different compounds, fluorescein, 
which are filled into the right half of the reservoirs, and sulforhodamine, which are filled 






We demonstrated the fabrication of a MEMS device with built-in multiple-arrays 
of drug reservoirs that can provide controlled drug release depending on the degradation 
of a covering polymer film.  This device could be implanted in the body, for instance 
underneath the skin or adjacent to tissues such as the eye.  By varying the film thickness, 
we can achieve a drug releasing period from weeks up to a month.  Multiple drug 





 One of the biggest challenges we faced in this study was to efficiently bind the 
covering polymer layer onto the base mold to avoid reservoir leakage.  Our study 
suggested that a better binding method could be a combination of ultrasonic welding and 
addition of a sealing layer around the contact edges.  However, besides using a 
degradable polymer film with a thickness gradient, removing the covering of the 
reservoirs can be controlled by other mechanisms also.  One possibility is to have a 
uniform covering film with various channels of different geometric design (length, 
pattern, etc.) to guide the drug release.  The channels can also be filled with another 
material that may further slow the drug transport and release.  Another method is to 
fabricate the covering with different materials that undergo inductive heating in the 
presence of an alternating electromagnetic field.  By applying a certain electromagnetic 
frequency, the corresponding inductive heating material would then be excited to get hot, 
whereas other inductive materials, with a different characteristic frequency, would not.  
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